MONASH University

AUSTRALIAN NATIONAL DIABETES AUDIT

2022

Supplement

ads Australian Diabetes Society

nadc National Association of Diabetes Centres

CONTENTS

ACKNOWLEDGEMENTS

The Australian National Diabetes Audit (ANDA) 2022 has been supported by funding from the Australian Government Department of Health and Aged Care. ANDA is operated by the Project Executive Team at the School of Public Health and Preventive Medicine (SPHPM), Monash University.

We are grateful for the contributions made by the ANDA Scientific Advisory Committee. We acknowledge the leadership of the chair of the Scientific Advisory Committee, who is also the project lead and data custodian, Professor Sophia Zoungas. We also acknowledge the Project Executive at SPHPM and their contributions.

We would like to thank the participating diabetes services and their patients for their generous contribution to this work. ANDA would not be possible without the ongoing efforts of the many clinicians, nurses, and other relevant staff at the services who collect data and manage the ANDA-related activities.

We gratefully acknowledge the significant support and championing of this project over many years by the National Association of Diabetes Centres (NADC), a division of the Australian Diabetes Society (ADS).

In the spirit of reconciliation, we acknowledge the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

ANDA Project Executive

Professor Sophia Zoungas - Project Lead
Ms Dimitra Giannopoulos - Project Manager/ Secretariat
Professor Susannah Ahern - Technical Advisor
A/Professor Arul Earnest - Senior Biostatistician
Dr Ella Zomer - Research Lead
Dr Ahmad Reza Pourghaderi - Senior Data Analyst
Dr Lavanya Gupta - Clinical Research Fellow
Dr Anthony Pease - Clinical Researcher
Ms Trieu-Anh Truong - Data Manager
Mrs Claudia Lassetter - Communications Manager
Ms Mahima Choudhary - Research Support Officer
Ms Kara Kotsovolos - Administrative Officer
Mr Matthew Quigley - PhD Candidate

ANDA Scientific Advisory Committee

Professor Sophia Zoungas - Project Lead
A/Professor Sofianos Andrikopoulos - Australian Diabetes Society (ADS) Representative
Ms Taryn Black - Diabetes Australia Representative
A/Professor Wendy Davis - Data/Science Expert
Professor Barbora de Courten - Clinical Representative
Dr Gary Deed - Primary Health Sector Representative
Professor Jeff Flack - Clinical Representative
Professor Jenny Gunton - Clinical Representative
Mr Trevor Jones - Consumer Representative
Dr Konrad Kangru - Primary Health Sector Representative
Ms Faith Margrie - Australian Government Department of Health and Aged Care Representative
Dr Odette Pearson - Aboriginal and Torres Strait Islander Representative and Data/Science Expert
Ms Megan Phelan - Australian Government Department of Health and Aged Care Representative
Ms Sally Rayner - Australian Government Department of Health and Aged Care Representative
Professor Jane Speight - Data/Science Expert
Ms Natalie Wischer - National Association of Diabetes Centres (NADC) Representative

ABBREVIATIONS AND ACRONYMS

ACE	Angiotensin Converting Enzyme
ADS	Australian Diabetes Society
ANDA	Australian National Diabetes Audit
ARB	Angiotensin II Receptor Blockers
BMI	Body Mass Index
BP	Blood Pressure
CABG	Coronary Artery Bypass Graft
CGM	Continuous Glucose Monitoring
COVID-19	Coronavirus Disease 2019
DKA	Diabetic Ketoacidosis
DPP4	Dipeptidyl Peptidase IV
DOB	Date of Birth
DVA	Department of Veterans Affairs
eGFR	Estimated Glomerular Filtration Rate
EASD	European Association for the Study of Diabetes
GDM	Gestational Diabetes Mellitus
GLP1	Glucagon-Like Peptide-1
HbA_{1c}	Glycated Haemoglobin
HDL	High Density Lipoprotein
IQR	Interquartile Range
LDL	Low-Density Lipoprotein
METeOR	Metadata Online Registry
NADC	National Association of Diabetes Centres
NDDWG	National Diabetes Data Working Group
NDOQRIN	National Diabetes Outcomes Quality Review Initiative
NDOW	NSW Diabetes Outcome Workshop
NDSS	National Diabetes Services Scheme
NICE	National Institute for Health and Care Excellence
NSW	New South Wales
SGLT2	Sodium-Glucose Co-Transporter 2
SPHPM	School of Public Health and Preventative Medicine
SD	Standard Deviation
T1DM	Type 1 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus

1. ORIGINS OF THE ANDA DATASET

There has been longstanding worldwide interest in developing suitable diabetes datasets and methods of data collection to capture appropriate diabetes outcomes for quality improvement. As a result, collection, analysis and reporting of standardised diabetes datasets is now widely practised. The European Association for the Study of Diabetes (EASD) Study Group DO IT (Diabetes care Optimisation through Information Technology)[1] undertook much work aimed at improving the quality of diabetes care through the appropriate use of information technology, including promoting the collection, analysis and reporting of the DiabCare dataset [2, 3] for audit and benchmarking purposes. From this has come the DiabCare Q-Net initiative.[4]

A similar initiative, the NSW Diabetes Outcomes Workshop (NDOW), was undertaken in Australia in September 1993 with funding from the NSW Health Department.[5, 6] Forty-five stakeholders including diabetes health professionals, Health Department officials and consumers met for a one-day workshop and agreed on a dataset of 59 health outcome data elements that covered demographic, acute and chronic complications and self-care practice areas of diabetes care. These items became known as the NDOW dataset, and subsequently these data items have become widely promulgated for collection (using standardised definitions) across Australia.

In 1997 the Australian Diabetes Society (ADS) Council accepted a recommendation to adopt the NDOW dataset as its Diabetes Outcomes dataset, and formed a sub-committee (now named the National Diabetes Data Working Group (NDDWG)). This sub-committee managed the dataset and promoted quality diabetes care in Australia, through the National Diabetes Outcomes Quality Review INitiative, (NDOQRIN). The NDDWG has taken a subset of the NDOW dataset and has promoted its collection as a minimum dataset (for quality diabetes care) in a variety of clinical practice settings.

After diabetes was named the 5th National Health Priority Area in 1996,[7] work followed to improve diabetes care in Australia including the commissioning of the National Diabetes Strategy to update and replace the National Action Plan. One aspect reviewed was the need for local data on which appropriate planning could be carried out and assessment of the effect of initiatives could be undertaken. Consequently, several initiatives indicated the need for reliable data in Australia (including diabetes indicators work), as noted in the National Health Priority Areas Report: Diabetes Mellitus 1998.[7] However, data on clinical aspects of diabetes, including outcomes data, were deficient in Australia as highlighted in The National Diabetes Strategy and Implementation Plan report.[8]

The NDDWG continued to promulgate the NDOQRIN dataset, and in 2002 was successful in having it accepted as the first clinical dataset to be included in the National Health Data Dictionary and Knowledgebase, Version 12. This dataset has since been enhanced, and is now online as part of the AIHW – Metadata Online Registry ('METeOR') as the Diabetes (clinical) Data Set Specification.[9]

The NDOQRIN minimal dataset was utilised for the inaugural ANDA data collection in 1998 (then known as the Australian National Diabetes Information Audit & Benchmarking, ANDIAB). Subsequent enhancements have been made on a biennial basis to incorporate new research on diabetes quality clinical indicators, and to address feedback from centres participating in the previous audit cycle. The ANDA dataset has been reviewed for consistency with international datasets for diabetes benchmarking. There are high rates of agreement between the ANDA dataset and international diabetes benchmarking datasets, including the Diabetes Quality Indicators Project in the US,[10] the National Board of Health and Welfare Quality Indicators in Sweden,[11] and the National Institute for Health and Care Excellence Diabetes Quality Indicators in the United Kingdom.[12]

2. DATA QUERIES

Missing vital data fields:
A list was generated of all instances of missing data in any of the following fields: Sex, date of birth, year of diagnosis, diabetes type, diabetes management, height, weight, initial visit, fasting status (if lipids recorded).

Potentially invalid data values:
A list was generated to check potential data inaccuracies as follows:

(1) Male = Pregnant OR Female <18 or >55 = Pregnant
(2) Type 1 and insulin not indicated
(3) GDM and not currently pregnant
(4) Year of Diagnosis or Year Started Insulin < Date of birth
(5) On insulin since - Year < Date of diagnosis
(6) Systolic BP < diastolic BP OR systolic or diastolic is missing
(7) Systolic BP <70mmHg or >200mmHg OR diastolic BP <40mmHg or >130mmHg
(8) Age >18 years and height <1.3 metres or >2.2 metres
(9) Age >18 years and weight <40 kilograms or >200 kilograms
(10) BMI >50 kg/m^2
(11) Age >18 years and BMI <15 kg/m^2
(12) Type 1 and on insulin ≥3 years after date of diagnosis
(13) Age <2 years

Whilst some of the scenarios may be possible (e.g. 7, 8, 9), the likelihood is that they represent incorrect data recording or interpretation by the computer system.

Possible duplicates*:* (double individual registration/data entry), based on sex, date of birth, country of birth match.

Potentially incorrect HbA_{1c}, lipid, and creatinine values*:* HbA_{1c} <4%, HbA_{1c} <20 mmol/mol, total cholesterol <2.0 mmol/L, HDL cholesterol >2.5 mmol/L, triglyceride <0.5 mmol/L, creatinine <50 or >1000 µmol/L.

3. DATA ASSUMPTIONS, DECISIONS AND MANIPULATIONS

As in previous years, data assumptions and decisions were made based on the following rules.
Only patients aged 18 and above were included in the pooled analysis. In 2022, the results of patients with GDM and paediatric patients (aged under 18 years) were presented separately.

Missing data were also calculated conditionally where relevant:

- Date of visit=1/06/2022 if missing
- Pregnancy=Yes, if female and has GDM
- Insulin=Yes, if insulin duration and/mode indicated

Invalid data were excluded:

- Date of birth after visit date
- Pregnancy if male or female aged >55 years
- Urinary protein/albumin value, if units not indicated
- Type 1 and insulin use not indicated, unless < 12 months since diagnosis
- 'Year of diagnosis' and 'Insulin duration' excluded if < date of birth
- Proportion of time using sensors if continuous/flash glucose monitoring not indicated

Data manipulations and derivation

- Age was calculated: Current year – Year of birth. If visit date was unavailable, date was assumed to be 1st June of the report year.
- Duration of diabetes was calculated: Current year - Year of diagnosis
- Only unknown/missing diabetes type, were reclassified to T1DM using the following criteria:
  - If patient was on insulin therapy and pump (this applies for any age at diagnosis and any time from diagnosis to insulin therapy – as long as there is no missing data)
  - If age at diagnosis <30 years and time from diagnosis to insulin therapy ≤1 year and patient was on insulin therapy
  - If age at diagnosis <30 years and time from diagnosis to insulin therapy (>1 and <3) years and patient is on insulin therapy and (basal bolus or pump)
- Only unknown/missing diabetes type, were reclassified to T2DM using the following criteria:
  - If age at diagnosis ≥30 years and time from diagnosis to insulin therapy ≥3 years and patient was on insulin therapy
- Anti-hypertensive therapy changed to 'No' if no medications were indicated
- 'Diet only' changed to 'No' if other management methods details were indicated
- 'Lipid modifying therapy' changed to 'No' if no therapy details were indicated
- BMI was calculated: weight (kg)/height $(m)^2$. If height was greater than 2.5, it was assumed that it was reported in metres instead of centimetres.
- Urinary protein/albumin assessment was considered in relation to published guidelines for laboratory thresholds
- Instances where patients reported multiple modes of insulin, the following hierarchical algorithm was used: Hybrid closed loop system > Pump > Basal bolus > Pre-mixed > Basal
- Lipid non-HDL cholesterol was calculated: Total cholesterol – HDL cholesterol
- Since the first COVID-19 vaccination date in Australia was 23-02-2021, any dates reported earlier were ignored

Descriptive Reports

The descriptive reports provide a breakdown of data by diabetes type for patient characteristics and outcomes. Raw data are demonstrated in tabular or descriptive format, and the corresponding bar charts demonstrate the mean or percentage by collection site. In each table, R% reflects the percentage of patients by variable options, e.g. males versus females. Alternatively, C% reflects the percentage of patients in each variable by sub-group, e.g. diabetes type (T1DM, T2DM, don't know, other or unstated). In each bar chart, individual bars across the x-axis represent a single data collection site, and the y-axis corresponds to the mean or percentage at the individual site for that characteristic. The bars are presented in descending order, with the data from a site with the highest mean or percentage presented on the left. Note that there are variable numbers of bars across different charts - as data for certain characteristics were not recorded at every site. At the site level, the distribution of key clinical outcomes appeared normally distributed for the majority of outcomes and therefore the means are utilised in the descriptive reports. For duration of diabetes and triglycerides, median values are utilised as the data were not normally distributed.

Missing Data

Missing data are reported as frequency and percentage. Percentage is calculated from the total number of applicable respondents (for example; missing pregnancy data is calculated from the total number of female patients of reproductive age).

4. FREQUENCY COUNT DATA (ADULTS)

SECTION 1. PATIENT DEMOGRAPHICS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth									
		DOB	4640	100.0%	100%					
		Missing	1	0.0%						
		Sum	**4641**	**100%**	**100%**					
	Age									
		Age (years)	4640	100.0%	100%	60.4	57.2	17.7	18.0	100.8
		Missing	1	0.0%						
		Sum	**4641**	**100%**	**100%**					
1.2	Sex									
		Male	2522	54.3%	54.5%					
		Female	2106	45.4%	45.5%					
		Missing	13	0.3%						
		Sum	**4641**	**100%**	**100%**					
1.2.1	Currently pregnant (females aged 18-55 years)									
		Yes	42	4.6%	5.3%					
		No	747	81.9%	94.7%					
		Missing	123	13.5%						
		Sum	**912**	**100%**	**100%**					
1.3	Date of visit									
		Visit Date	4641	100.0%	100%					
		Missing	0	0.0%						
		Sum	**4641**	**100%**	**100%**					
1.4	Initial visit									
		Yes	817	17.6%	17.8%					
		No	3761	81.0%	82.2%					
		Missing	63	1.4%						
		Sum	**4641**	**100%**	**100%**					
1.5	Aboriginal/Torres Strait Islander									
		Yes	322	6.9%	7.6%					
		No	3938	84.9%	92.4%					
		Missing	381	8.2%						
		Sum	**4641**	**100%**	**100%**					
1.6	Interpreter required									
		Yes	122	2.6%	2.9%					
		No	4043	87.1%	97.1%					
		Missing	476	10.3%						
		Sum	**4641**	**100%**	**100%**					
1.7	NDSS member									
		Yes	3656	78.8%	88.5%					
		No	475	10.2%	11.5%					
		Missing	510	11.0%						
		Sum	**4641**	**100%**	**100%**					
1.8	Country of birth									
		Country	4180	90%	100%					
		Missing	461	9.9%						
		Sum	**4641**	**100%**	**100%**					
1.9	DVA patient									
		Yes	75	1.6%	1.8%					
		No	4072	87.7%	98.2%					
		Missing	494	10.6%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Date of diagnosis									
		Year	4520	97.4%	100%					
		Missing	121	2.6%						
		Sum	4641	100%	100%					
	Diabetes duration					Median	IQR		Min	Max
		Diabetes duration (years)	4520	97.4%	100%	12.5	5.4 - 22.4		0.0	70.5
		Missing	121	2.6%						
		Sum	4641	100%	100%					
2.2	Type of diabetes									
		T1DM	1407	30.3%	30.6%					
		T2DM	2935	63.2%	63.9%					
		Don't know	136	2.9%	3.0%					
		Other	116	2.5%	2.5%					
		Missing	47	1.0%						
		Sum	4641	100%	100%					
2.3	Blood glucose monitoring									
		None	490	10.6%	10.8%					
		Finger pricking**	3057	65.9%	67.1%					
		Continuous glucose monitoring**	452	9.7%	9.9%					
		Flash glucose monitoring**	441	9.5%	9.7%					
		Missing	386	8.3%						
	** multiple methods reported in some patients									
2.3.1	Check as often as recommended**									
		Yes	1911	62.5%	64.1%					
		No	915	29.9%	30.7%					
		Unsure	157	5.1%	5.3%					
		Missing	74	2.4%						
		Sum	3057	100%	100%					
2.3.2	Number of times a day**					Median	Mean	SD	Min	Max
		Provided	2999	98.1%	100.0%	2.0	2.4	1.7	0.0	20.0
		Missing	58	1.9%						
		Sum	3057	100%	100%					
	** of patients using finger pricking									
2.3.3	Proportion of time using sensors**									
		<50%	113	12.7%	13.3%					
		50-75%	97	10.9%	11.4%					
		>75-100%	638	71.8%	75.2%					
		Missing	41	4.6%						
		Sum	889	100%	100%					
	** of patients using flash/continuous glucose monitoring									

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.4	Management method									
		Diet only	149	3.2%	3.3%					
		Metformin**	2355	50.7%	51.7%					
		Sulphonylurea**	633	13.6%	13.9%					
		Glitazone**	24	0.5%	0.5%					
		Acarbose**	12	0.3%	0.3%					
		DPP4 inhibitor**	620	13.4%	13.6%					
		SGLT2 inhibitor**	960	20.7%	21.1%					
		GLP1 agonist**	1035	22.3%	22.7%					
		Insulin**	3113	67.1%	68.3%					
		Missing	86	1.9%						
	** monotherapy or in combination with other treatments									
2.4.1	Insulin duration**									
		<1 year	375	12.0%	13.3%					
		1-5 years	644	20.7%	22.9%					
		>5 years	1796	57.7%	63.8%					
		Missing	298	9.6%						
		Sum	**3113**	**100%**	**100%**					
2.4.2	Insulin mode**									
		Basal†	698	15.0%	23.3%					
		Basal bolus†	1438	31.0%	47.9%					
		Pump†	296	6.4%	9.9%					
		Pre-mixed insulin†	795	17.1%	26.5%					
		Hybrid closed loop system†	60	1.3%	2.0%					
		Missing	100	2.2%						
	** of patients on insulin									
	† multiple modes of insulin reported in some patients									

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & BLOOD PRESSURE (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1a	Weight									
		Weight (kg)	4289	92.4%	100%	86.0	89.2	24.1	15.4	250.0
		Missing	352	7.6%						
		Sum	**4641**	**100%**	**100%**					
3.1b	Weight (self-reported)									
		Yes	1130	26.3%	27.2%					
		No	3031	70.7%	72.8%					
		Missing	128	3.0%						
		Sum	**4289**	**100%**	**100%**					
3.2a	Height									
		Height (m)	4034	86.9%	100%	1.7	1.7	0.1	1.3	2.0
		Missing	607	13.1%						
		Sum	**4641**	**100%**	**100%**					
3.2b	Height (self-reported)									
		Yes	1219	30.2%	31.3%					
		No	2681	66.5%	68.7%					
		Missing	134	3.3%						
		Sum	**4034**	**100%**	**100%**					
3.3	Systolic blood pressure									
		Systolic (mmHg)	3747	80.7%	100%	130	132	17	84	220
		Missing	894	19.3%						
		Sum	**4641**	**100%**	**100%**					
3.3	Diastolic blood pressure									
		Diastolic (mmHg)	3747	80.7%	100%	78	77	11	38	133
		Missing	894	19.3%						
		Sum	**4641**	**100%**	**100%**					
3.4	Anti-hypertensive therapy									
		Yes	2560	55.2%	59.9%					
		No	1716	37.0%	40.1%					
		Missing	365	7.9%						
		Sum	**4641**	**100%**	**100%**					
3.4.1	Anti-hypertensive therapies**									
		ACE inhibitor†	1134	24.4%	26.5%					
		Thiazide†	313	6.7%	7.3%					
		Calcium channel blocker†	781	16.8%	18.3%					
		Beta blocker†	756	16.3%	17.7%					
		ARB†	982	21.2%	23.0%					
		Other anti-hypertensive†	312	6.7%	7.3%					
		Missing	365	7.9%						

** of patients on anti-hypertensive therapy

† multiple modes of insulin reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Aspirin									
		Yes	1108	23.9%	25.9%					
		No	3154	68.0%	73.8%					
		Contraindicated	12	0.3%	0.3%					
		Missing	367	7.9%						
		Sum	**4641**	**100%**	**100.0%**					
4.2	Other anti-platelets									
		Yes	271	5.8%	6.4%					
		No	3989	86.0%	93.6%					
		Contraindicated	4	0.1%	0.1%					
		Missing	377	8.1%						
		Sum	**4641**	**100%**	**100.0%**					
4.3	Anti-coagulants									
		Yes	328	7.1%	7.7%					
		No	3933	84.7%	92.3%					
		Contraindicated	1	0.0%	0.0%					
		Missing	379	8.2%						
		Sum	**4641**	**100%**	**100%**					
4.4	Lipid modifying therapy									
		Yes	2582	55.6%	60.0%					
		No	1723	37.1%	40.0%					
		Missing	336	7.2%						
		Sum	**4641**	**100%**	**100%**					
4.4.1	Statin**									
		Yes	2412	93.4%	93.7%					
		No	147	5.7%	5.7%					
		Contraindicated	16	0.6%	0.6%					
		Missing	7	0.3%						
		Sum	**2582**	**100%**	**100%**					
4.4.2	Fibrate**									
		Yes	308	11.9%	12.3%					
		No	2186	84.7%	87.4%					
		Contraindicated	7	0.3%	0.3%					
		Missing	81	3.1%						
		Sum	**2582**	**100%**	**100%**					
4.4.3	Ezetimibe**									
		Yes	335	13.0%	13.4%					
		No	2161	83.7%	86.3%					
		Contraindicated	7	0.3%	0.3%					
		Missing	79	3.1%						
		Sum	**2582**	**100%**	**100%**					
4.4.4	Fish oil**									
		Yes	128	5.0%	5.1%					
		No	2366	91.6%	94.7%					
		Contraindicated	4	0.2%	0.2%					
		Missing	84	3.3%						
		Sum	**2582**	**100%**	**100%**					
4.4.5	Evolocumab**									
		Yes	11	0.4%	0.4%					
		No	2433	94.2%	99.4%					
		Contraindicated	4	0.2%	0.2%					
		Missing	134	5.2%						
		Sum	**2582**	**100%**	**100%**					
4.4.6	Other lipid modifying therapy**									
		Yes	36	1.4%	1.5%					
		No	2394	92.7%	98.2%					
		Contraindicated	9	0.3%	0.4%					
		Missing	143	5.5%						
		Sum	**2582**	**100%**	**100%**					

** of patients on lipid modifying therapy

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.5	Lipids measured									
		Yes	2837	61.1%	61.1%					
		No	1804	38.9%	38.9%					
		Missing	0	0.0%						
		Sum	4641	100%	100%					
4.5.1	Total cholesterol**									
		Total cholesterol (mmol/L)	2814	99.2%	100%	4.1	4.3	1.5	1.3	47.0
		Missing	23	0.8%						
		Sum	2837	100%	100%					
4.5.2	LDL**									
		LDL (mmol/L)	2396	84.5%	100%	2.1	2.2	1.0	0.1	14.4
		Missing	441	15.5%						
		Sum	2837	100%	100%					
4.5.3	HDL**									
		HDL (mmol/L)	2442	86.1%	100%	1.1	1.2	0.4	0.1	4.4
		Missing	395	13.9%						
		Sum	2837	100%	100%					
4.5.4	Triglycerides**					Median	IQR		Min	Max
		Triglycerides (mmol/L)	2768	97.6%	100%	1.6	1.1 - 2.4		0.2	76.1
		Missing	69	2.4%						
		Sum	2837	100%	100%					
4.5.5	Fasting lipids**									
		Yes	2189	77.2%	80.5%					
		No	531	18.7%	19.5%					
		Missing	117	4.1%						
		Sum	2837	100%	100%					

** of patients with lipids measured

*Relative % = % of the total excluding the missing values

SECTION 5. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	**HbA_{1c} result (%)**									
		HbA_{1c} (%)	3838	82.7%	100%	8.0	8.4	1.9	4.2	18.7
		Missing	803	17.3%						
		Sum	**4641**	**100%**	**100%**					
5.1.1	**HbA_{1c} (%) test date**									
		HbA_{1c} (%) test date provided	3838	82.7%	100%					
		Missing	803	17.3%						
		Sum	**4641**	**100%**	**100%**					
5.2	**eGFR**									
		eGFR (mL/min per 1.73m^2)	3549	76.5%	100%	84.0	74.0	24.9	0.0	740.0
		Missing	1092	23.5%						
		Sum	**4641**	**100%**	**100%**					
5.3	**Serum creatinine**									
		Creatinine (µmol/L)	3448	74.3%	100%	80.0	97.1	81.7	4.0	1437.0
		Missing	1193	25.7%						
		Sum	**4641**	**100%**	**100%**					
5.4a	**Urinary albumin result (all units)**									
		Result	2256	48.6%	100%					
		Missing	2385	51.4%						
		Sum	**4641**	**100%**	**100%**					
	Urinary albumin result (mg/L)					**Median**	**IQR**		**Min**	**Max**
		Result	1203	25.9%	100%	15.0	5 - 58		0.0	6019.0
	Urinary albumin result (µg/min)									
		Result	7	0.2%	100%	9.4	6 - 32		3.0	81.6
	Urinary albumin result (mg/24hr)									
		Result	4	0.1%	100%	82.4	26 - 174		7.0	300.0
	Albumin:creatinine (ratio)									
		Result	1042	22.5%	100%	2.0	1.0 - 7.0		0.0	2008.0
5.4b	**Urinary protein result (all units)**									
		Result	537	11.6%	100%					
		Missing	4104	88.4%						
		Sum	**4641**	**100%**	**100%**					
	Urinary protein result (mg/L)									
		Result	101	2.2%	100%	29.0	4.0 - 39.0		0.0	6061.2
	Urinary protein result (µg/min)									
		Result	1	0.0%	100%	0.8	2.0 - 33.0		0.8	0.8
	Urinary protein result (mg/24hr)									
		Result	3	0.1%	100%	71.0	2.0 - 306.0		0.3	7111.0
	Protein:creatinine (ratio)									
		Result	432	9.3%	100%	2.0	1.0 - 8.0		0.0	1467.0

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED EYE & FOOT DISEASES (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Retinopathy - last 12 months									
		Yes	684	14.7%	16.0%					
		No	3603	77.6%	84.0%					
		Missing	354	7.6%						
		Sum	**4641**	**100%**	**100%**					
	Retinopathy - previous									
		Yes	769	16.6%	18.4%					
		No	3409	73.5%	81.6%					
		Missing	463	10.0%						
		Sum	**4641**	**100%**	**100%**					
6.2	Treatment for retinopathy - last 12 months									
		Yes	275	5.9%	6.4%					
		No	3994	86.1%	93.6%					
		Missing	372	8.0%						
		Sum	**4641**	**100%**	**100%**					
	Treatment for retinopathy - previous									
		Yes	474	10.2%	11.4%					
		No	3697	79.7%	88.6%					
		Missing	470	10.1%						
		Sum	**4641**	**100%**	**100%**					
6.3	Right or left cataract - last 12 months									
		Yes	502	10.8%	11.7%					
		No	3781	81.5%	88.3%					
		Missing	358	7.7%						
		Sum	**4641**	**100%**	**100%**					
	Right or left cataract - previous									
		Yes	686	14.8%	16.4%					
		No	3493	75.3%	83.6%					
		Missing	462	10.0%						
		Sum	**4641**	**100%**	**100%**					
6.4	Peripheral neuropathy - last 12 months									
		Yes	904	19.5%	21.0%					
		No	3398	73.2%	79.0%					
		Missing	339	7.3%						
		Sum	**4641**	**100%**	**100%**					
	Peripheral neuropathy - previous									
		Yes	762	16.4%	18.2%					
		No	3414	73.6%	81.8%					
		Missing	465	10.0%						
		Sum	**4641**	**100%**	**100%**					
6.5	Foot ulceration - last 12 months									
		Yes	228	4.9%	5.3%					
		No	4083	88.0%	94.7%					
		Missing	330	7.1%						
		Sum	**4641**	**100%**	**100%**					
	Foot ulceration - previous									
		Yes	274	5.9%	6.5%					
		No	3973	85.6%	93.5%					
		Missing	394	8.5%						
		Sum	**4641**	**100%**	**100%**					
6.6	Peripheral vascular disease - last 12 months									
		Yes	365	7.9%	8.5%					
		No	3938	84.9%	91.5%					
		Missing	338	7.3%						
		Sum	**4641**	**100%**	**100%**					
	Peripheral vascular disease - previous									
		Yes	319	6.9%	7.7%					
		No	3849	82.9%	92.3%					
		Missing	473	10.2%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED FOOT PROBLEMS (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.7a	Lower limb amputation - last 12 months									
		Yes	76	1.6%	1.8%					
		No	4234	91.2%	98.2%					
		Missing	331	7.1%						
		Sum	**4641**	**100%**	**100%**					
	Minor lower limb amputation - last 12 months									
		Yes	52	68.4%	68.4%					
		No	24	31.6%	31.6%					
		Missing	0	0.0%						
		Sum	**76**	**100%**	**100%**					
	Major lower limb amputation - last 12 months									
		Yes	22	28.9%	28.9%					
		No	54	71.1%	71.1%					
		Missing	0	0.0%						
		Sum	**76**	**100%**	**100%**					
6.7b	Lower limb amputation - previous									
		Yes	110	2.4%	2.6%					
		No	4074	87.8%	97.4%					
		Missing	457	9.8%						
		Sum	**4641**	**100%**	**100%**					
	Minor lower limb amputation - previous									
		Yes	79	71.8%	71.8%					
		No	31	28.2%	28.2%					
		Missing	0	0.0%						
		Sum	**110**	**100%**	**100%**					
	Major lower limb amputation - previous									
		Yes	29	26.4%	26.4%					
		No	81	73.6%	73.6%					
		Missing	0	0.0%						
		Sum	**110**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Stroke - last 12 months									
		Yes	67	1.4%	1.5%					
		No	4264	91.9%	98.5%					
		Missing	310	6.7%						
		Sum	**4641**	**100%**	**100%**					
	Stroke - previous									
		Yes	226	4.9%	5.4%					
		No	3993	86.0%	94.6%					
		Missing	422	9.1%						
		Sum	**4641**	**100%**	**100%**					
7.2	Myocardial infarction - last 12 months									
		Yes	119	2.6%	2.7%					
		No	4212	90.8%	97.3%					
		Missing	310	6.7%						
		Sum	**4641**	**100%**	**100%**					
	Myocardial infarction - previous									
		Yes	417	9.0%	9.9%					
		No	3804	82.0%	90.1%					
		Missing	420	9.0%						
		Sum	**4641**	**100%**	**100%**					
7.3	CABG/Angioplasty - last 12 months									
		Yes	122	2.6%	2.8%					
		No	4206	90.6%	97.2%					
		Missing	313	6.7%						
		Sum	**4641**	**100%**	**100%**					
	CABG/Angioplasty - previous									
		Yes	431	9.3%	10.2%					
		No	3790	81.7%	89.8%					
		Missing	420	9.0%						
		Sum	**4641**	**100%**	**100%**					
7.4	Congestive cardiac failure - last 12 months									
		Yes	177	3.8%	4.2%					
		No	4028	86.8%	95.8%					
		Missing	436	9.4%						
		Sum	**4641**	**100%**	**100%**					
	Congestive cardiac failure - previous									
		Yes	187	4.0%	4.5%					
		No	3970	85.5%	95.5%					
		Missing	484	10.4%						
		Sum	**4641**	**100%**	**100%**					
7.5	End stage kidney disease - last 12 months									
		Yes	186	4.0%	4.3%					
		No	4141	89.2%	95.7%					
		Missing	314	6.8%						
		Sum	**4641**	**100%**	**100%**					
	End stage kidney disease - previous									
		Yes	205	4.4%	4.9%					
		No	4013	86.5%	95.1%					
		Missing	423	9.1%						
		Sum	**4641**	**100%**	**100%**					
7.6	Blindness - last 12 months									
		Yes	84	1.8%	2.0%					
		No	4166	89.8%	98.0%					
		Missing	391	8.4%						
		Sum	**4641**	**100%**	**100%**					
	Blindness - previous									
		Yes	74	1.6%	1.8%					
		No	4094	88.2%	98.2%					
		Missing	473	10.2%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.7	Sexual dysfunction - last 12 months									
		Yes	504	10.9%	12.1%					
		No	3649	78.6%	87.9%					
		Missing	488	10.5%						
		Sum	**4641**	**100%**	**100%**					
	Sexual dysfunction - previous									
		Yes	504	10.9%	12.1%					
		No	3649	78.6%	87.9%					
		Missing	488	10.5%						
		Sum	**4641**	**100%**	**100%**					
7.8	Dementia - last 12 months									
		Yes	127	2.7%	3.0%					
		No	4078	87.9%	97.0%					
		Missing	436	9.4%						
		Sum	**4641**	**100%**	**100%**					
	Dementia - previous									
		Yes	89	1.9%	2.1%					
		No	4075	87.8%	97.9%					
		Missing	477	10.3%						
		Sum	**4641**	**100%**	**100%**					
7.9	Depression - last 12 months									
		Yes	841	18.1%	20.0%					
		No	3362	72.4%	80.0%					
		Missing	438	9.4%						
		Sum	**4641**	**100%**	**100%**					
	Depression - previous									
		Yes	908	19.6%	21.8%					
		No	3262	70.3%	78.2%					
		Missing	471	10.1%						
		Sum	**4641**	**100%**	**100%**					
7.10	Malignancy - last 12 months									
		Yes	152	3.3%	3.6%					
		No	4053	87.3%	96.4%					
		Missing	436	9.4%						
		Sum	**4641**	**100%**	**100%**					
	Malignancy - previous									
		Yes	305	6.6%	7.3%					
		No	3858	83.1%	92.7%					
		Missing	478	10.3%						
		Sum	**4641**	**100%**	**100%**					
7.11	Diabetic ketoacidosis - last 12 months									
		Yes	144	3.1%	3.4%					
		No	4090	88.1%	96.6%					
		Missing	407	8.8%						
		Sum	**4641**	**100%**	**100%**					
	Diabetic ketoacidosis - previous									
		Yes	378	8.1%	9.0%					
		No	3822	82.4%	91.0%					
		Missing	441	9.5%						
		Sum	**4641**	**100%**	**100%**					
7.12	Hyperosmolar hyperglycaemic state - last 12 months									
		Yes	34	0.7%	0.8%					
		No	4190	90.3%	99.2%					
		Missing	417	9.0%						
		Sum	**4641**	**100%**	**100%**					
	Hyperosmolar hyperglycaemic state - previous									
		Yes	51	1.1%	1.2%					
		No	4127	88.9%	98.8%					
		Missing	463	10.0%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (ADULTS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.13	Severe hypoglycaemia - last 12 months									
		Yes	181	3.9%	4.2%					
		No	4085	88.0%	95.8%					
		Missing	375	8.1%						
		Sum	**4641**	**100%**	**100%**					
7.13.1	Number of episodes									
		1-2 episodes	107	59.1%	63.3%					
		3-5 episodes	37	20.4%	21.9%					
		>5 episodes	25	13.8%	14.8%					
		Missing	12	6.6%						
		Sum	**181**	**100%**	**100%**					
	** of patients with severe hypoglycaemia									
	Severe hypoglycaemia - previous									
		Yes	334	7.2%	8.0%					
		No	3817	82.2%	92.0%					
		Missing	490	10.6%						
		Sum	**4641**	**100%**	**100%**					
7.14	COVID-19 - last 12 months									
		Yes	829	17.9%	20.3%					
		No	3260	70.2%	79.7%					
		Missing	552	11.9%						
		Sum	**4641**	**100%**	**100%**					
7.14.1	COVID-19 hospital admission - last 12 months**									
		Yes	70	8.4%	8.5%					
		No	751	90.6%	91.5%					
		Missing	8	1.0%						
		Sum	**829**	**100%**	**100%**					
	** of patients who have had COVID-19 in the last 12 months									
	COVID-19 - previous									
		Yes	62	1.3%	1.5%					
		No	3947	85.0%	98.5%					
		Missing	632	13.6%						
		Sum	**4641**	**100%**	**100%**					
	COVID-19 hospital admission - previous**									
		Yes	5	8.1%	8.2%					
		No	56	90.3%	91.8%					
		Missing	1	1.6%						
		Sum	**62**	**100%**	**100%**					
	** of patients who have had COVID-19 prior to the last 12 months									
7.15	Liver disease									
		Mild	418	9.0%	10.1%					
		Moderate/severe	181	3.9%	4.4%					
		Not applicable	3556	76.6%	85.6%					
		Missing	486	10.5%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 8. MENTAL HEALTH SCREENING (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
8.1	Screened for depression									
		Yes	931	20.1%	22.1%					
		No	2652	57.1%	62.9%					
		Unsure	632	13.6%	15.0%					
		Missing	426	9.2%						
		Sum	**4641**	**100%**	**100%**					
8.2	Screened for anxiety									
		Yes	749	16.1%	17.8%					
		No	2808	60.5%	66.6%					
		Unsure	657	14.2%	15.6%					
		Missing	427	9.2%						
		Sum	**4641**	**100%**	**100%**					
8.3	Screened for diabetes distress									
		Yes	383	8.3%	9.1%					
		No	3145	67.8%	74.6%					
		Unsure	685	14.8%	16.3%					
		Missing	428	9.2%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

PATIENT HEALTH & WELL-BEING QUESTIONNAIRE

SECTION 1. SMOKING & VACCINATION STATUS (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Smoking status - current									
		Currently smoke	614	13.2%	14.9%					
		Not currently smoking	3519	75.8%	85.1%					
		Missing	508	10.9%						
		Sum	**4641**	**100%**	**100%**					
1.1.1	Smoking status - past**									
		Previously smoked	1259	35.8%	36.5%					
		Previously did not smoke	2187	62.1%	63.5%					
		Missing	73	2.1%						
		Sum	**3519**	**100%**	**100%**					
	** of patients who are not current smokers									
1.2	COVID-19 vaccination									
		Yes	3725	80.3%	93.3%					
		No	268	5.8%	6.7%					
		Missing	648	14.0%						
		Sum	**4641**	**100%**	**100%**					
1.2.1	COVID-19 vaccination - number of doses **									
		1	32	0.9%	0.9%					
		2	689	18.5%	18.5%					
		3	2372	63.7%	63.7%					
		4	608	16.3%	16.3%					
		5	6	0.2%	0.2%					
		Missing	18	0.5%						
		Sum	**3725**	**100%**	**100%**					
1.2.2	COVID-19 vaccination - date of last dose **									
		Date provided	2232	59.9%	59.9%					
		I do not remember	1493	40.1%	40.1%					
		Missing	0	0.0%						
		Sum	**3725**	**100%**	**100%**					
	** of patients who have had a COVID-19 vaccination									
1.3	Influenza vaccination									
		Yes	2570	55.4%	64.8%					
		No	1398	30.1%	35.2%					
		Missing	673	14.5%						
		Sum	**4641**	**100%**	**100%**					
1.4	Pneumococcal vaccination									
		Yes	426	9.2%	10.8%					
		No	3523	75.9%	89.2%					
		Missing	692	14.9%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 2. HEALTH PROFESSIONAL ATTENDANCES (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Attended endocrinologist									
		Yes	2754	59.3%	67.1%					
		No	1264	27.2%	30.8%					
		Unsure	85	1.8%	2.1%					
		Missing	538	11.6%						
		Sum	**4641**	**100%**	**100%**					
2.2	Attended diabetes educator									
		Yes	2692	58.0%	66.0%					
		No	1318	28.4%	32.3%					
		Unsure	71	1.5%	1.7%					
		Missing	560	12.1%						
		Sum	**4641**	**100%**	**100%**					
2.3	Attended dietitian									
		Yes	1454	31.3%	35.9%					
		No	2495	53.8%	61.5%					
		Unsure	105	2.3%	2.6%					
		Missing	587	12.6%						
		Sum	**4641**	**100%**	**100%**					
2.4	Attended podiatrist									
		Yes	2089	45.0%	51.3%					
		No	1865	40.2%	45.8%					
		Unsure	122	2.6%	3.0%					
		Missing	565	12.2%						
		Sum	**4641**	**100%**	**100%**					
2.5	Attended ophthalmologist									
		Yes	1203	25.9%	29.6%					
		No	2675	57.6%	65.8%					
		Unsure	188	4.1%	4.6%					
		Missing	575	12.4%						
		Sum	**4641**	**100%**	**100%**					
2.6	Attended optometrist									
		Yes	2606	56.2%	64.0%					
		No	1330	28.7%	32.6%					
		Unsure	138	3.0%	3.4%					
		Missing	567	12.2%						
		Sum	**4641**	**100%**	**100%**					
2.7	Attended psychologist									
		Yes	447	9.6%	11.0%					
		No	3413	73.5%	84.3%					
		Unsure	189	4.1%	4.7%					
		Missing	592	12.8%						
		Sum	**4641**	**100%**	**100%**					
2.8	Attended social worker									
		Yes	224	4.8%	5.5%					
		No	3629	78.2%	89.7%					
		Unsure	194	4.2%	4.8%					
		Missing	594	12.8%						
		Sum	**4641**	**100%**	**100%**					
2.9	Attended dentist									
		Yes	1490	32.1%	36.7%					
		No	2338	50.4%	57.6%					
		Unsure	230	5.0%	5.7%					
		Missing	583	12.6%						
		Sum	**4641**	**100%**	**100%**					
2.10	Attended physiologist/physiotherapist									
		Yes	662	14.3%	16.3%					
		No	3190	68.7%	78.7%					
		Unsure	201	4.3%	5.0%					
		Missing	588	12.7%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 3. MEDICATION USE (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Ever forget to take medications									
		Yes	931	20.1%	23.2%					
		No	2957	63.7%	73.6%					
		Not applicable	130	2.8%	3.2%					
		Missing	623	13.4%						
		Sum	**4641**	**100%**	**100%**					
3.1.1	Number of times per week**									
		Provided	913	98.1%	100.0%	1.0	1.9	1.7	0.0	10.0
		Missing	18	1.9%						
		Sum	**931**	**100%**	**100%**					

** of patients who forget to take medications

SECTION 4. PATIENT SELF CARE PRACTICES (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Diet - Difficulties following recommended diet									
		Yes	1163	25.1%	29.0%					
		No	2849	61.4%	71.0%					
		Missing	629	13.6%						
		Sum	**4641**	**100.0%**	**100.0%**					
4.1.1	Diet - Not enough time to prepare healthy meals**									
		Yes	430	37.0%	37.9%					
		No	704	60.5%	62.1%					
		Missing	29	2.5%						
		Sum	**1163**	**100.0%**	**100.0%**					
4.1.2	Diet - It costs too much to eat well**									
		Yes	430	37.0%	37.9%					
		No	704	60.5%	62.1%					
		Missing	29	2.5%						
		Sum	**1163**	**100.0%**	**100.0%**					
4.1.3	Diet - I don't know what foods are best to eat**									
		Yes	350	30.1%	30.9%					
		No	781	67.2%	69.1%					
		Missing	32	2.8%						
		Sum	**1163**	**100.0%**	**100.0%**					
4.1.4	Diet - I eat out a lot and find it hard to eat well**									
		Yes	278	23.9%	24.6%					
		No	853	73.3%	75.4%					
		Missing	32	2.8%						
		Sum	**1163**	**100.0%**	**100.0%**					
4.1.5	Diet - Too hard to count carbs/weigh food (of T1DM patients)**									
		Yes	189	57.6%	59.6%					
		No	128	39.0%	40.4%					
		Missing	11	3.4%						
		Sum	**328**	**100.0%**	**100.0%**					

** of patients who have difficulties following recommended diet

SECTION 5. PHYSICAL ACTIVITY (ADULTS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Moderate or vigorous intensity physical activity									
		150 mins/week or more	1223	26.4%	30.5%					
		Less than 150 mins/week	1256	27.1%	31.3%					
		Rarely/never	1537	33.1%	38.3%					
		Missing	625	13.5%						
		Sum	**4641**	**100.0%**	**100.0%**					
5.2	Muscle strengthening									
		Yes	1260	27.1%	31.7%					
		No	2720	58.6%	68.3%					
		Missing	661	14.2%						
		Sum	**4641**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

4.1 FREQUENCY COUNT DATA (GDM)

SECTION 1. PATIENT DEMOGRAPHICS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth									
		DOB	188	100.0%	100%					
		Missing	0	0.0%						
		Sum	188	100%	100%					
1.2	Age									
		Age	188	100.0%	100%	32.6	32.7	6.2	16.2	66.1
		Missing	0	0.0%						
		Sum	188	100%	100%					
1.3	Date of visit									
		Visit Date	188	100%	100%					
		Missing	0	0.0%						
		Sum	188	100%	100%					
1.4	Initial visit									
		Yes	99	52.7%	53.2%					
		No	87	46.3%	46.8%					
		Missing	2	1.1%						
		Sum	188	100%	100%					
1.5	Aboriginal/Torres Strait Islander									
		Yes	19	10.1%	10.2%					
		No	168	89.4%	89.8%					
		Missing	1	0.5%						
		Sum	188	100%	100%					
1.6	Interpreter required									
		Yes	7	3.7%	3.8%					
		No	179	95.2%	96.2%					
		Missing	2	1.1%						
		Sum	188	100%	100%					
1.7	NDSS member									
		Yes	109	58.0%	58.3%					
		No	78	41.5%	41.7%					
		Missing	1	0.5%						
		Sum	188	100%	100%					
1.8	Country of birth									
		Country	179	95%	100%					
		Missing	9	4.8%						
		Sum	188	100%	100%					
1.9	DVA patient									
		Yes	0	0.0%	0.0%					
		No	187	99.5%	100.0%					
		Missing	1	0.5%						
		Sum	188	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Year of diagnosis									
		Year	69	36.7%	100%					
		Missing	119	63.3%						
		Sum	**188**	**100%**	**100%**					
2.2	Duration of diabetes					Median	IQR		Min	Max
		Duration	186	98.9%	100%	0.1	0.1 - 0.2		0.0	5.4
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
2.3	Blood glucose monitoring									
		None	50	26.6%	26.6%					
		Finger pricking**	138	73.4%	73.4%					
		Continuous glucose monitoring**	1	0.5%	0.5%					
		Flash glucose monitoring**	0	0.0%	0.0%					
		Missing	0	0.0%						
	** multiple methods reported in some patients									
2.3.1	Check as often as recommended **									
		Yes	109	79.0%	79.6%					
		No	5	3.6%	3.6%					
		Unsure	23	16.7%	16.8%					
		Missing	1							
		Sum	**138**	**99%**	**100%**					
2.3.2	Number of times a day**					Median	Mean	SD	Min	Max
		Provided	137	99.3%	100.0%	4.0	3.9	0.6	1.0	6.0
		Missing	1	0.7%						
		Sum	**138**	**100%**	**100%**					
	** of patients using finger pricking									
2.3.3	Proportion of time using sensors**									
		<50%	1	100.0%	100.0%					
		50-75%	0	NA	0.0%					
		>75-100%	0	NA	0.0%					
		Missing	0	NA						
		Sum	**1**	**1**	**100%**					
	** of patients using flash/continuous glucose monitoring									
2.4	Management method									
		Diet only	117	62.2%	62.2%					
		Metformin**	21	11.2%	11.2%					
		Sulphonylurea**	0	0.0%	0.0%					
		Glitazone**	0	0.0%	0.0%					
		Acarbose**	0	0.0%	0.0%					
		DPP4 inhibitor**	0	0.0%	0.0%					
		SGLT2 inhibitor**	0	0.0%	0.0%					
		GLP1 agonist**	1	0.5%	0.5%					
		Insulin**	70	37.2%	37.2%					
		Missing	0	0.0%						
	** monotherapy or in combination with other treatments									
2.4.1	Insulin duration**									
		<1 year	68	97.1%	98.6%					
		1-5 years	1	1.4%	1.4%					
		>5 years	0	0.0%	0.0%					
		Missing	1	1.4%						
		Sum	**70**	**100%**	**100%**					
2.4.2	Insulin mode**									
		Basal†	38	20.2%	55.9%					
		Basal bolus†	29	15.4%	42.6%					
		Pump†	0	NA	0.0%					
		Pre-mixed insulin†	2	1.1%	2.9%					
		Hybrid closed loop system†	0	NA	0.0%					
		Missing	2	1.1%						
	** of patients on insulin									
	† multiple modes of insulin reported in some patients									

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & BLOOD PRESSURE (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	**Weight**									
		Weight	183	97.3%	100%	87.8	90.6	22.3	47.0	157.0
		Missing	5	2.7%						
		Sum	**188**	**100%**	**100%**					
3.1b	**Weight (self-reported)**									
		Yes	56	30.6%	30.8%					
		No	126	68.9%	69.2%					
		Missing	1	0.5%						
		Sum	**183**	**100%**	**100%**					
3.2	**Height**									
		Height	180	95.7%	100%	1.7	1.6	0.1	1.4	1.8
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
3.2b	**Height (self-reported)**									
		Yes	76	42.2%	42.5%					
		No	103	57.2%	57.5%					
		Missing	1	0.6%						
		Sum	**180**	**100%**	**100%**					
3.3	**Systolic blood pressure**									
		Systolic	156	83.0%	100%	116	115	12	90	152
		Missing	32	17.0%						
		Sum	**188**	**100%**	**100%**					
3.3	**Diastolic blood pressure**									
		Diastolic	156	83.0%	100%	70	70	9	45	90
		Missing	32	17.0%						
		Sum	**188**	**100%**	**100%**					
3.4	**Anti-hypertensive treatment**									
		Yes	6	3.2%	3.2%					
		No	181	96.3%	96.8%					
		Missing	1	0.5%						
		Sum	**188**	**100%**	**100%**					
3.4.1	**Anti-hypertensive therapies****									
		ACE inhibitor†	0	NA	0.0%					
		Thiazide†	1	0.5%	0.5%					
		Calcium channel blocker†	1	0.5%	0.5%					
		Beta blocker†	4	2.1%	2.1%					
		ARB†	1	0.5%	0.5%					
		Other anti-hypertensive†	3	1.6%	1.6%					
		Missing	1	0.5%						

**of patients on anti-hypertensive therapy

† multiple therapies reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Aspirin									
		Yes	23	12.2%	12.3%					
		No	164	87.2%	87.7%					
		Contraindicated	0	0.0%	0.0%					
		Missing	1	0.5%						
		Sum	**188**	**100%**	**100.0%**					
4.2	Other anti-platelets									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	99.5%					
		Contraindicated	1	0.5%	0.5%					
		Missing	1	0.5%						
		Sum	**188**	**100%**	**100.0%**					
4.3	Anti-coagulants									
		Yes	9	4.8%	4.8%					
		No	178	94.7%	95.2%					
		Contraindicated	0	0.0%	0.0%					
		Missing	1	0.5%						
		Sum	**188**	**100%**	**100%**					
4.4	Lipid modifying therapy									
		Yes	3	1.6%	1.6%					
		No	184	97.9%	98.4%					
		Missing	1	0.5%						
		Sum	**188**	**100%**	**100%**					
4.4.1	Statin**									
		Yes	1	33.3%	33.3%					
		No	2	66.7%	66.7%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					
4.4.2	Fibrate**									
		Yes	0	0.0%	0.0%					
		No	3	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					
4.4.3	Ezetimibe**									
		Yes	0	0.0%	0.0%					
		No	3	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					
4.4.4	Fish oil**									
		Yes	2	66.7%	66.7%					
		No	1	33.3%	33.3%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					
4.4.5	Evolocumab**									
		Yes	0	0.0%	0.0%					
		No	3	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					
4.4.6	Other lipid modifying therapy**									
		Yes	0	0.0%	0.0%					
		No	3	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**3**	**100%**	**100%**					

** of patients on lipid modifying therapy

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (GDM) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.5	Lipids measured									
		Yes	16	8.5%	8.5%					
		No	172	91.5%	91.5%					
		Missing	0	0.0%						
		Sum	**188**	**100%**	**100%**					
4.5.1	Total cholesterol**									
		Total cholesterol	16	100.0%	100%	4.8	5.1	1.1	3.8	8.4
		Missing	0	0.0%						
		Sum	**16**	**100%**	**100%**					
4.5.2	LDL**									
		LDL	10	62.5%	100%	2.7	2.7	0.6	1.5	3.7
		Missing	6	37.5%						
		Sum	**16**	**100%**	**100%**					
4.5.3	HDL**									
		HDL	11	68.8%	100%	1.4	1.5	0.4	0.9	2.2
		Missing	5	31.3%						
		Sum	**16**	**100%**	**100%**					
4.5.4	Triglycerides**					**Median**	**IQR**		**Min**	**Max**
		Triglycerides	16	100.0%	100%	1.6	1.0 - 2.3		0.5	10.2
		Missing	0	0.0%						
		Sum	**16**	**100%**	**100%**					
4.5.5	Fasting lipids**									
		Yes	7	43.8%	43.8%					
		No	9	56.3%	56.3%					
		Missing	0	0.0%						
		Sum	**16**	**100%**	**100%**					

** of patients with lipids measured

*Relative % = % of the total excluding the missing values

SECTION 5. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	HbA1c result (%)									
		HbA1c	41	21.8%	100%	5.2	5.5	0.9	4.3	8.8
		Missing	147	78.2%						
		Sum	**188**	**100%**	**100%**					
5.1.1	HbA1c (%) test date									
		HbA1c (%) test date provided	41	21.8%	100%					
		Missing	147	78.2%						
		Sum	**188**	**100%**	**100%**					
5.2	eGFR									
		eGFR (mL/min per 1.73m^2)	79	42.0%	100%	90.0	89.6	2.0	76.0	90.0
		Missing	109	58.0%						
		Sum	**188**	**100%**	**100%**					
5.3	Serum creatinine									
		Creatinine (µmol/L)	86	45.7%	100%	52.0	53.8	10.8	27.0	82.0
		Missing	102	54.3%						
		Sum	**188**	**100%**	**100%**					
5.4a	Urinary albumin result (all units)									
		Result	8	4.3%	100%					
		Missing	180	95.7%						
		Sum	**188**	**100%**	**100%**					
	Urinary albumin result (mg/L)					**Median**	**IQR**		**Min**	**Max**
		Result	3	1.6%	100%	110.0	5.0 - 115.0		5.0	115.0
	Urinary albumin result (µg/min)									
		Result	0	NA	NA	NA	NA		NA	NA
	Urinary albumin result (mg/24hr)									
		Result	0	NA	NA	NA	NA		NA	NA
	Albumin:creatinine (ratio)									
		Result	5	2.7%	100%	11.0	8.0 - 32.0		6.3	32.0
5.4b	Urinary protein result (all units)									
		Result	13	6.9%	100%					
		Missing	175	93.1%						
		Sum	**188**	**100%**	**100%**					
	Urinary protein result (mg/L)									
		Result	3	1.6%	100%	16.0	14.0 - 24.0		0.0	32.0
	Urinary protein result (µg/min)									
		Result	1	0.5%	100%	32.0	32.0 - 32.0		0.0	32.0
	Urinary protein result (mg/24hr)									
		Result	0	NA	NA	NA	NA		NA	NA
	Protein:creatinine (ratio)									
		Result	9	4.8%	100%	13.0	11.0 - 14.0		0.0	21.0

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED EYE & FOOT DISEASES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Retinopathy - last 12 months									
		Yes	1	0.5%	0.5%					
		No	185	98.4%	99.5%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Retinopathy - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
6.2	Treatment for retinopathy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Treatment for retinopathy - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
6.3	Right or left cataract - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Right or left cataract - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
6.4	Peripheral neuropathy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Peripheral neuropathy - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
6.5	Foot ulceration - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Foot ulceration - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
6.6	Peripheral vascular disease - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Peripheral vascular disease - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED EYE & FOOT DISEASES (GDM) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.7	Lower limb amputation - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Lower limb amputation - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Stroke - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Stroke - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.2	Myocardial infarction - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Myocardial infarction - previous									
		Yes	1	0.5%	0.5%					
		No	185	98.4%	99.5%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.3	CABG/Angioplasty - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	CABG/Angioplasty - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.4	Congestive cardiac failure - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Congestive cardiac failure - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.5	End stage kidney disease - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	End stage kidney disease - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (GDM) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.6	Blindness - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Blindness - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.7	Sexual dysfunction - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Sexual dysfunction - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.8	Dementia - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Dementia - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.9	Depression - last 12 months									
		Yes	24	12.8%	12.9%					
		No	162	86.2%	87.1%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Depression - previous									
		Yes	28	14.9%	15.1%					
		No	158	84.0%	84.9%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.10	Malignancy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Malignancy - previous									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.11	Diabetic ketoacidosis - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Diabetic ketoacidosis - previous									
		Yes	1	0.5%	0.5%					
		No	185	98.4%	99.5%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (GDM) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.12	Hyperosmolar hyperglycaemic state - last 12 months									
		Yes	0	0.0%	0.0%					
		No	186	98.9%	100.0%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
	Hyperosmolar hyperglycaemic state - previous									
		Yes	1	0.5%	0.5%					
		No	185	98.4%	99.5%					
		Missing	2	1.1%						
		Sum	**188**	**100%**	**100%**					
7.13	Severe hypoglycaemia - last 12 months									
		Yes	1	0.5%	0.5%					
		No	184	97.9%	99.5%					
		Missing	3	1.6%						
		Sum	**188**	**100%**	**100%**					
7.13.1	Number of episodes									
		1-2 episodes	1	NA	100.0%					
		3-5 episodes	0	NA	0.0%					
		>5 episodes	0	NA	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**NA**	**100%**					
	** of patients with severe hypoglycaemia									
	Severe hypoglycaemia - previous									
		Yes	0	0.0%	0.0%					
		No	185	98.4%	100.0%					
		Missing	3	1.6%						
		Sum	**188**	**100%**	**100%**					
7.14	COVID-19 - last 12 months									
		Yes	53	28.2%	28.8%					
		No	131	69.7%	71.2%					
		Missing	4	2.1%						
		Sum	**188**	**100%**	**100%**					
7.14.1	COVID-19 hospital admission - last 12 months**									
		Yes	4	7.5%	7.5%					
		No	49	92.5%	92.5%					
		Missing	0	0.0%						
		Sum	**53**	**100%**	**100%**					
	** of patients who have had COVID-19 in the last 12 months									
	COVID-19 - previous									
		Yes	7	3.7%	3.8%					
		No	176	93.6%	96.2%					
		Missing	5	2.7%						
		Sum	**188**	**100%**	**100%**					
	COVID-19 hospital admission - previous**									
		Yes	0	0.0%	0.0%					
		No	7	100.0%	100.0%					
		Missing	0	0.0%						
		Sum	**7**	**100%**	**100%**					
	** of patients who have had COVID-19 prior to the last 12 months									
7.15	Liver disease									
		Mild	2	1.1%	1.1%					
		Moderate/severe	1	0.5%	0.5%					
		Not applicable	182	96.8%	98.4%					
		Missing	3	1.6%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

PATIENT HEALTH & WELL-BEING QUESTIONNAIRE

SECTION 1. SMOKING & VACCINATION STATUS (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Smoking status - current									
		Currently smoke	13	6.9%	7.3%					
		Not currently smoking	166	88.3%	92.7%					
		Missing	9	4.8%						
		Sum	**188**	**100%**	**100%**					
1.1.1	Smoking status - past**									
		Previously smoked	152	91.6%	91.6%					
		Previously did not smoke	14	8.4%	8.4%					
		Missing	0	0.0%						
		Sum	**166**	**100%**	**100%**					
	** of patients who are not current smokers									
1.2	COVID-19 vaccination									
		Yes	165	87.8%	91.7%					
		No	15	8.0%	8.3%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
1.2.1	COVID-19 vaccination - number of doses **									
		1	0	NA	0.0%					
		2	73	44.2%	44.2%					
		3	90	54.5%	54.5%					
		4	1	0.6%	0.6%					
		5	0	NA	0.0%					
		Missing	1	0.6%						
		Sum	**165**	**100%**	**99%**					
1.2.2	COVID-19 vaccination - date of last dose **									
		Date provided	82	49.7%	49.7%					
		I do not remember	83	50.3%	50.3%					
		Missing	0	0.0%						
		Sum	**165**	**100%**	**100%**					
	** of patients who have had a COVID-19 vaccination									
1.3	Influenza vaccination									
		Yes	97	51.6%	53.9%					
		No	83	44.1%	46.1%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
1.4	Pneumococcal vaccination									
		Yes	7	3.7%	3.9%					
		No	173	92.0%	96.1%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 2. HEALTH PROFESSIONAL ATTENDANCES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Attended endocrinologist									
		Yes	70	37.2%	38.9%					
		No	109	58.0%	60.6%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.2	Attended diabetes educator									
		Yes	106	56.4%	58.6%					
		No	75	39.9%	41.4%					
		Unsure	0	0.0%	0.0%					
		Missing	7	3.7%						
		Sum	**188**	**100%**	**100%**					
2.3	Attended dietitian									
		Yes	89	47.3%	49.4%					
		No	91	48.4%	50.6%					
		Unsure	0	0.0%	0.0%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.4	Attended podiatrist									
		Yes	2	1.1%	1.1%					
		No	177	94.1%	98.3%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.5	Attended ophthalmologist									
		Yes	1	0.5%	0.6%					
		No	178	94.7%	98.9%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.6	Attended optometrist									
		Yes	24	12.8%	13.3%					
		No	154	81.9%	85.6%					
		Unsure	2	1.1%	1.1%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.7	Attended psychologist									
		Yes	17	9.0%	9.4%					
		No	162	86.2%	90.0%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.8	Attended social worker									
		Yes	8	4.3%	4.4%					
		No	171	91.0%	95.0%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.9	Attended dentist									
		Yes	61	32.4%	33.9%					
		No	118	62.8%	65.6%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
2.10	Attended physiologist/physiotherapist									
		Yes	9	4.8%	5.0%					
		No	170	90.4%	94.4%					
		Unsure	1	0.5%	0.6%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 3. MEDICATION USE (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Ever forget to take medications									
		Yes	23	12.2%	12.8%					
		No	124	66.0%	68.9%					
		Not applicable	33	17.6%	18.3%					
		Missing	8	4.3%						
		Sum	**188**	**100%**	**100%**					
3.1.1	Number of times per week**									
		Provided	23	100.0%	100.0%	1.0	1.7	1.3	0.0	6.0
		Missing	0	0.0%						
		Sum	**23**	**100%**	**100%**					

** of patients who forget to take medications

SECTION 4. PATIENT SELF CARE PRACTICES (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Diet - Difficulties following recommended diet									
		Yes	44	23.4%	24.4%					
		No	136	72.3%	75.6%					
		Missing	8	4.3%						
		Sum	**188**	**100.0%**	**100.0%**					
4.1.1	Diet - Not enough time to prepare healthy meals**									
		Yes	24	54.5%	55.8%					
		No	19	43.2%	44.2%					
		Missing	1	2.3%						
		Sum	**44**	**100.0%**	**100.0%**					
4.1.2	Diet - It costs too much to eat well**									
		Yes	24	54.5%	55.8%					
		No	19	43.2%	44.2%					
		Missing	1	2.3%						
		Sum	**44**	**100.0%**	**100.0%**					
4.1.3	Diet - I don't know what foods are best to eat**									
		Yes	16	36.4%	37.2%					
		No	27	61.4%	62.8%					
		Missing	1	2.3%						
		Sum	**44**	**100.0%**	**100.0%**					
4.1.4	Diet - I eat out a lot and find it hard to eat well**									
		Yes	8	18.2%	18.6%					
		No	35	79.5%	81.4%					
		Missing	1	2.3%						
		Sum	**44**	**100.0%**	**100.0%**					
4.1.5	Diet - Too hard to count carbs/weigh food (of T1DM patients)**									
		Yes	0	NA	NA					
		No	0	NA	NA					
		Missing	0	NA						
		Sum	**NA**	**NA**	**NA**					

** of patients who have difficulties following recommended diet

SECTION 5. PHYSICAL ACTIVITY (GDM)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Moderate or vigorous intensity physical activity									
		150 mins/week or more	47	25.0%	26.1%					
		Less than 150 mins/week	87	46.3%	48.3%					
		Rarely/never	46	24.5%	25.6%					
		Missing	8	4.3%						
		Sum	**188**	**100.0%**	**100.0%**					
5.2	Muscle strengthening									
		Yes	41	21.8%	22.9%					
		No	138	73.4%	77.1%					
		Missing	9	4.8%						
		Sum	**188**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

4.2 FREQUENCY COUNT DATA (PAEDIATRICS)

SECTION 1. PATIENT DEMOGRAPHICS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Date of birth									
		DOB	415	100.0%	100%					
		Missing	0	0.0%						
		Sum	415	100%	100%					
	Age									
		Age (years)	415	100.0%	100%	13.8	13.2	3.3	2.0	18.0
		Missing	0	0.0%						
		Sum	415	100%	100%					
1.2	Sex									
		Male	210	50.6%	50.6%					
		Female	205	49.4%	49.4%					
		Missing	0	0.0%						
		Sum	415	100%	100%					
1.2.1	Currently pregnant (females aged 12-<18 years)									
		Yes	0	0.0%	0.0%					
		No	146	98.6%	100.0%					
		Missing	2	1.4%						
		Sum	148	100%	100%					
1.3	Date of visit									
		Visit Date	415	100.0%	100%					
		Missing	0	0.0%						
		Sum	415	100%	100%					
1.4	Initial visit									
		Yes	19	4.4%	4.5%					
		No	406	93.8%	95.5%					
		Missing	8	1.8%						
		Sum	433	100%	100%					
1.5	Aboriginal/Torres Strait Islander									
		Yes	24	5.8%	5.8%					
		No	390	94.0%	94.2%					
		Missing	1	0.2%						
		Sum	415	100%	100%					
1.6	Interpreter required									
		Yes	0	0.0%	0.0%					
		No	48	11.6%	100.0%					
		Missing	367	88.4%						
		Sum	415	100%	100%					
1.7	NDSS member									
		Yes	413	99.5%	99.8%					
		No	1	0.2%	0.2%					
		Missing	1	0.2%						
		Sum	415	100%	100%					
1.8	Country of birth									
		Country	415	100.0%	100%					
		Missing	0	0.0%						
		Sum	415	100%	100%					
1.9	DVA patient									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	415	100%	100%					

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Year of diagnosis									
		Year	414	99.8%	100%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Duration of diabetes					Median	IQR		Min	Max
		Duration (years)	414	99.8%	100%	4.1	1.9 - 7.2		0.0	18.5
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
2.2	Type of diabetes									
		T1DM	383	92.3%	93.0%					
		T2DM	25	6.0%	6.1%					
		GDM	0	0.0%	0.0%					
		Don't know	0	0.0%	0.0%					
		Other	4	1.0%	1.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
2.3	Blood glucose monitoring									
		None	22	5.3%	5.3%					
		Finger pricking**	37	8.9%	9.0%					
		Continuous glucose monitoring**	307	74.0%	74.3%					
		Flash glucose monitoring**	68	16.4%	16.5%					
		Missing	18	4.3%						
	** multiple methods reported in some patients									
2.3.1	Check as often as recommended**									
		Yes	14	37.8%	43.8%					
		No	18	48.6%	56.3%					
		Unsure	0	0.0%	0.0%					
		Missing	5							
		Sum	**37**	**86%**	**100%**					
2.3.2	Number of times a day**					Median	Mean	SD	Min	Max
		Provided	36	97.3%	100.0%	3.0	3.4	1.4	1.0	6.0
		Missing	1	2.7%						
		Sum	**37**	**100%**	**100%**					
	** of patients using finger pricking									
2.3.3	Proportion of time using sensors**									
		<50%	41	11.5%	12.4%					
		50-75%	68	19.0%	20.6%					
		>75-100%	221	61.7%	67.0%					
		Missing	28	7.8%						
		Sum	**358**	**100%**	**100%**					
	** of patients using flash/continuous glucose monitoring									

*Relative % = % of the total excluding the missing values

SECTION 2. DIABETES TYPE & MANAGEMENT (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.4	Management method									
		Diet only	1	0.2%	0.2%					
		Metformin**	23	5.5%	5.6%					
		Sulphonylurea**	0	0.0%	0.0%					
		Glitazone**	0	0.0%	0.0%					
		Acarbose**	0	0.0%	0.0%					
		DPP4 inhibitor**	1	0.2%	0.2%					
		SGLT2 inhibitor**	2	0.5%	0.5%					
		GLP1 agonist**	1	0.2%	0.2%					
		Insulin**	402	96.9%	97.3%					
		Missing	2	0.5%						
	** monotherapy or in combination with other treatments									
2.4.1	**Insulin duration****									
		<1 year	59	14.7%	14.8%					
		1-5 years	194	48.3%	48.5%					
		>5 years	147	36.6%	36.8%					
		Missing	2	0.5%						
		Sum	**402**	**100%**	**100%**					
2.4.2	**Insulin mode****									
		Basal†	175	42.2%	50.0%					
		Basal bolus†	175	42.2%	50.0%					
		Pump†	179	43.1%	51.1%					
		Pre-mixed insulin†	0	NA	0.0%					
		Hybrid closed loop system†	46	11.1%	13.1%					
		Missing	51	12.3%						
	** of patients on insulin									
	† multiple modes of insulin reported in some patients									

*Relative % = % of the total excluding the missing values

SECTION 3. HEIGHT, WEIGHT & BLOOD PRESSURE (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Weight									
		Weight (kg)	173	41.7%	100%	56.2	60.2	24.6	5.4	240.0
		Missing	242	58.3%						
		Sum	415	100%	100%					
3.1b	Weight (self-reported)									
		Yes	3	1.7%	1.8%					
		No	165	95.4%	98.2%					
		Missing	5	2.9%						
		Sum	173	100%	100%					
3.2	Height									
		Height (m)	149	35.9%	100%	1.6	1.6	0.2	0.9	2.1
		Missing	266	64.1%						
		Sum	415	100%	100%					
3.2b	Height (self-reported)									
		Yes	1	0.7%	0.7%					
		No	142	95.3%	99.3%					
		Missing	6	4.0%						
		Sum	149	100%	100%					
3.3	Systolic blood pressure									
		Systolic (mmHg)	64	15.4%	100%	109	110	14	84	215
		Missing	351	84.6%						
		Sum	415	100%	100%					
3.3	Diastolic blood pressure									
		Diastolic (mmHg)	64	15.4%	100%	70	69	9	53	130
		Missing	351	84.6%						
		Sum	415	100%	100%					
3.4	Anti-hypertensive therapy									
		Yes	3	0.7%	0.7%					
		No	409	98.6%	99.3%					
		Missing	3	0.7%						
		Sum	415	100%	100%					
3.4.1	Anti-hypertensive therapies**									
		ACE inhibitor†	3	0.7%	0.7%					
		Thiazide†	0	NA	0.0%					
		Calcium channel blocker†	0	NA	0.0%					
		Beta blocker†	1	0.2%	0.2%					
		ARB†	0	NA	0.0%					
		Other anti-hypertensive†	0	NA	0.0%					
		Missing	3	0.7%						

**of patients on anti-hypertensive therapy

† multiple therapies reported in some patients

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Aspirin									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100.0%**					
4.2	Other anti-platelets									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100.0%**					
4.3	Anti-coagulants									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
4.4	Lipid modifying therapy									
		Yes	1	0.2%	0.2%					
		No	412	99.3%	99.8%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
4.4.1	Statin**									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					
4.4.2	Fibrate**									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					
4.4.3	Ezetimibe**									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					
4.4.4	Fish oil**									
		Yes	1	100.0%	100.0%					
		No	0	0.0%	0.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					
4.4.5	Evolocumab**									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					
4.4.6	Other lipid modifying therapy**									
		Yes	0	0.0%	0.0%					
		No	1	100.0%	100.0%					
		Contraindicated	0	0.0%	0.0%					
		Missing	0	0.0%						
		Sum	**1**	**100%**	**100%**					

** of patients on lipid modifying therapy

*Relative % = % of the total excluding the missing values

SECTION 4. MEDICATIONS & LIPIDS (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.5	Lipids measured									
		Yes	154	37.1%	37.1%					
		No	261	62.9%	62.9%					
		Missing	0	0.0%						
		Sum	415	100%	100%					
4.5.1	Total cholesterol**									
		Total cholesterol (mmol/L)	154	100.0%	100%	4.4	4.5	1.0	2.0	9.8
		Missing	0	0.0%						
		Sum	154	100%	100%					
4.5.2	LDL**									
		LDL (mmol/L)	129	83.8%	100%	2.5	2.6	0.9	0.0	6.0
		Missing	25	16.2%						
		Sum	154	100%	100%					
4.5.3	HDL**									
		HDL (mmol/L)	130	84.4%	100%	1.5	1.5	0.4	0.6	2.8
		Missing	24	15.6%						
		Sum	154	100%	100%					
4.5.4	Triglycerides**					Median	IQR		Min	Max
		Triglycerides (mmol/L)	151	98.1%	100%	0.9	0.6 - 1.3		0.3	6.5
		Missing	3	1.9%						
		Sum	154	100%	100%					
4.5.5	Fasting lipids**									
		Yes	35	22.7%	22.9%					
		No	118	76.6%	77.1%					
		Missing	1	0.6%						
		Sum	154	100%	100%					

** of patients with lipids measured

*Relative % = % of the total excluding the missing values

SECTION 5. RENAL FUNCTION & BLOOD GLUCOSE CONTROL (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	**HbA_{1c} result (%)**									
		HbA_{1c} (%)	135	32.5%	100%	7.9	8.3	1.7	0.0	0.0
		Missing	280	67.5%						
		Sum	**415**	**100%**	**100%**					
5.1.1	**HbA1c (%) test date**									
		HbA1c (%) 2022 date provided	135	32.5%	100%					
		Missing	280	67.5%						
		Sum	**415**	**100%**	**100%**					
5.2	**eGFR**									
		eGFR (mL/min per 1.73m^2)	5	1.2%	100%	90.0	108.0	24.9	0.0	140.0
		Missing	410	98.8%						
		Sum	**415**	**100%**	**100%**					
5.3	**Serum creatinine**									
		Creatinine (µmol/L)	19	4.6%	100%	52.0	63.5	18.9	36.0	0.0
		Missing	396	95.4%						
		Sum	**415**	**100%**	**100%**					
5.4a	**Urinary albumin result (all units)**									
		Result	99	23.9%	100%					
		Missing	316	76.1%						
		Sum	**415**	**100%**	**100%**					
	Urinary albumin result (mg/L)					**Median**	**IQR**		**Min**	**Max**
		Result	6	1.4%	100%	7.5	5.0 - 115.0		0.2	48.6
	Urinary albumin result (µg/min)									
		Result	0	NA	NA	NA	NA		NA	NA
	Urinary albumin result (mg/24hr)									
		Result	0	NA	NA	NA	NA		NA	NA
	Albumin:creatinine (ratio)									
		Result	93	22.4%	100%	11.0	8.0 - 32.0		0.1	170.4
5.4b	**Urinary protein result (all units)**									
		Result	4	1.0%	100%					
		Missing	411	99.0%						
		Sum	**415**	**100%**	**100%**					
	Urinary protein result (mg/L)									
		Result	1	0.2%	100%	17.0	14.0 - 24.0		0.4	17.0
	Urinary protein result (µg/min)									
		Result	0	NA	NA	NA	NA		NA	NA
	Urinary protein result (mg/24hr)									
		Result	0	NA	NA	NA	NA		NA	NA
	Protein:creatinine (ratio)									
		Result	3	0.7%	100%	0.4	11.0 - 14.0		0.4	0.9

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED EYE & FOOT DISEASES (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.1	Retinopathy - last 12 months									
		Yes	2	0.5%	0.5%					
		No	412	99.3%	99.5%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Retinopathy - previous									
		Yes	2	0.5%	0.5%					
		No	412	99.3%	99.5%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
6.2	Treatment for retinopathy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Treatment for retinopathy - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
6.3	Right or left cataract - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Right or left cataract - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
6.4	Peripheral neuropathy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Peripheral neuropathy - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
6.5	Foot ulceration - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Foot ulceration - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 6. DIABETES RELATED EYE & FOOT DISEASES (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
6.6	Peripheral vascular disease - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Peripheral vascular disease - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
6.7	Lower limb amputation - last 12 months									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					
	Lower limb amputation - previous									
		Yes	0	0.0%	0.0%					
		No	414	99.8%	100.0%					
		Missing	1	0.2%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.1	Stroke - last 12 months									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
	Stroke - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.2	Myocardial infarction - last 12 months									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
	Myocardial infarction - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.3	CABG/Angioplasty - last 12 months									
		Yes	0	0.0%	0.0%					
		No	413	99.5%	100.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
	CABG/Angioplasty - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.4	Congestive cardiac failure - last 12 months									
		Yes	0	0.0%	0.0%					
		No	412	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	Congestive cardiac failure - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.5	End stage kidney disease - last 12 months									
		Yes	0	0.0%	0.0%					
		No	412	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	End stage kidney disease - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.6	Blindness - last 12 months									
		Yes	0	0.0%	0.0%					
		No	412	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	Blindness - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 7. OTHER COMPLICATIONS/EVENTS/COMORBIDITIES (PAEDIATRICS) (continued)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.7	Sexual dysfunction - last 12 months									
		Yes	0	0.0%	0.0%					
		No	410	98.8%	100.0%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
	Sexual dysfunction - previous									
		Yes	0	0.0%	0.0%					
		No	410	98.8%	100.0%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
7.8	Dementia - last 12 months									
		Yes	0	0.0%	0.0%					
		No	412	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	Dementia - previous									
		Yes	0	0.0%	0.0%					
		No	410	98.8%	100.0%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
7.9	Depression - last 12 months									
		Yes	4	1.0%	1.0%					
		No	405	97.6%	99.0%					
		Missing	6	1.4%						
		Sum	**415**	**100%**	**100%**					
	Depression - previous									
		Yes	5	1.2%	1.2%					
		No	403	97.1%	98.8%					
		Missing	7	1.7%						
		Sum	**415**	**100%**	**100%**					
7.10	Malignancy - last 12 months									
		Yes	0	0.0%	0.0%					
		No	412	99.3%	100.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	Malignancy - previous									
		Yes	0	0.0%	0.0%					
		No	411	99.0%	100.0%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.11	Diabetic ketoacidosis - last 12 months									
		Yes	21	5.1%	5.1%					
		No	388	93.5%	94.9%					
		Missing	6	1.4%						
		Sum	**415**	**100%**	**100%**					
	Diabetic ketoacidosis - previous									
		Yes	30	7.2%	7.3%					
		No	379	91.3%	92.7%					
		Missing	6	1.4%						
		Sum	**415**	**100%**	**100%**					
7.12	Hyperosmolar hyperglycaemic state - last 12 months									
		Yes	1	0.2%	0.2%					
		No	411	99.0%	99.8%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
	Hyperosmolar hyperglycaemic state - previous									
		Yes	1	0.2%	0.2%					
		No	410	98.8%	99.8%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
7.13	Severe hypoglycaemia - last 12 months									
		Yes	18	4.3%	4.4%					
		No	393	94.7%	95.6%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
7.13.1	Number of episodes**									
		1-2 episodes	17	94.4%	100.0%					
		3-5 episodes	0	0.0%	0.0%					
		>5 episodes	0	0.0%	0.0%					
		Missing	1	5.6%						
		Sum	**18**	**100%**	**100%**					
	** of patients with severe hypoglycaemia									
	Severe hypoglycaemia - previous									
		Yes	86	20.7%	21.0%					
		No	324	78.1%	79.0%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
7.14	COVID-19 - last 12 months									
		Yes	65	15.7%	15.9%					
		No	345	83.1%	84.1%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
7.14.1	COVID-19 hospital admission - last 12 months**									
		Yes	1	1.5%	1.6%					
		No	62	95.4%	98.4%					
		Missing	2	3.1%						
		Sum	**65**	**100%**	**100%**					
	** of patients who have had COVID-19 in the last 12 months									
	COVID-19 - previous									
		Yes	1	0.2%	0.2%					
		No	405	97.6%	99.8%					
		Missing	9	2.2%						
		Sum	**415**	**100%**	**100%**					
	COVID-19 hospital admission - previous**									
		Yes	0	0.0%	NA					
		No	0	0.0%	NA					
		Missing	1	100.0%						
		Sum	**1**	**100%**	**NA**					
	** of patients who have had COVID-19 prior to the last 12 months									
7.15	Liver disease									
		Mild	2	0.5%	0.5%					
		Moderate/severe	0	0.0%	0.0%					
		Not applicable	406	97.8%	99.5%					
		Missing	7	1.7%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

PATIENT HEALTH & WELL-BEING QUESTIONNAIRE

SECTION 1. SMOKING & VACCINATION STATUS (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
1.1	Smoking status - current									
		Currently smoke	0	0.0%	0.0%					
		Not currently smoking	413	99.5%	100.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
1.1.1	Smoking status - past (of patients who are not current smokers)									
		Previously smoked	0	0.0%	0.0%					
		Previously did not smoke	401	97.1%	100.0%					
		Missing	12	2.9%						
		Sum	**413**	**100%**	**100%**					
1.2	COVID-19 vaccination									
		Yes	135	32.5%	32.9%					
		No	275	66.3%	67.1%					
		Missing	5	1.2%						
		Sum	**415**	**100%**	**100%**					
1.2.1	COVID-19 vaccination - number of doses **									
		1	10	7.4%	7.4%					
		2	110	81.5%	81.5%					
		3	15	11.1%	11.1%					
		4	0	NA	0.0%					
		5	0	NA	0.0%					
		Missing	0	0.0%						
		Sum	**135**	**100%**	**100%**					
1.2.2	COVID-19 vaccination - date of last dose **									
		Date provided	15	11.1%	11.1%					
		I do not remember	120	88.9%	88.9%					
		Missing	0	0.0%						
		Sum	**135**	**100%**	**100%**					
	** of patients who have had a COVID-19 vaccination									
1.3	Influenza vaccination									
		Yes	14	3.4%	31.1%					
		No	31	7.5%	68.9%					
		Missing	370	89.2%						
		Sum	**415**	**100%**	**100%**					
1.4	Pneumococcal vaccination									
		Yes	1	0.2%	2.5%					
		No	39	9.4%	97.5%					
		Missing	375	90.4%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 2. HEALTH PROFESSIONAL ATTENDANCES (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
2.1	Attended endocrinologist									
		Yes	412	99.3%	99.8%					
		No	1	0.2%	0.2%					
		Unsure	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.2	Attended diabetes educator									
		Yes	410	98.8%	99.3%					
		No	2	0.5%	0.5%					
		Unsure	1	0.2%	0.2%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.3	Attended dietitian									
		Yes	232	55.9%	56.2%					
		No	181	43.6%	43.8%					
		Unsure	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.4	Attended podiatrist									
		Yes	8	1.9%	1.9%					
		No	38	9.2%	9.2%					
		Unsure	365	88.0%	88.8%					
		Missing	4	1.0%						
		Sum	**415**	**100%**	**100%**					
2.5	Attended ophthalmologist									
		Yes	45	10.8%	10.9%					
		No	367	88.4%	89.1%					
		Unsure	0	0.0%	0.0%					
		Missing	3	0.7%						
		Sum	**415**	**100%**	**100%**					
2.6	Attended optometrist									
		Yes	31	7.5%	7.5%					
		No	17	4.1%	4.1%					
		Unsure	365	88.0%	88.4%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.7	Attended psychologist									
		Yes	40	9.6%	9.7%					
		No	373	89.9%	90.3%					
		Unsure	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.8	Attended social worker									
		Yes	152	36.6%	36.8%					
		No	261	62.9%	63.2%					
		Unsure	0	0.0%	0.0%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.9	Attended dentist									
		Yes	26	6.3%	6.3%					
		No	22	5.3%	5.3%					
		Unsure	365	88.0%	88.4%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					
2.10	Attended physiologist/physiotherapist									
		Yes	9	2.2%	2.2%					
		No	38	9.2%	9.2%					
		Unsure	366	88.2%	88.6%					
		Missing	2	0.5%						
		Sum	**415**	**100%**	**100%**					

*Relative % = % of the total excluding the missing values

SECTION 3. MEDICATION USE (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
3.1	Ever forget to take medications									
		Yes	9	2.2%	18.8%					
		No	39	9.4%	81.3%					
		Not applicable	0	0.0%	0.0%					
		Missing	367	88.4%						
		Sum	415	100%	100%					
3.1.1	Number of times per week**									
		Provided	9	100.0%	100.0%	3.0	2.6	1.3	1.0	4.0
		Missing	0	0.0%						
		Sum	9	100%	100%					

** of patients who forget to take medications

SECTION 4. PATIENT SELF CARE PRACTICES (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
4.1	Diet - Difficulties following recommended diet									
		Yes	10	2.4%	21.3%					
		No	37	8.9%	78.7%					
		Missing	368	88.7%						
		Sum	415	100.0%	100.0%					
4.1.1	Diet - Not enough time to prepare healthy meals**									
		Yes	1	10.0%	14.3%					
		No	6	60.0%	85.7%					
		Missing	3	30.0%						
		Sum	10	100.0%	100.0%					
4.1.2	Diet - It costs too much to eat well**									
		Yes	1	10.0%	14.3%					
		No	6	60.0%	85.7%					
		Missing	3	30.0%						
		Sum	10	100.0%	100.0%					
4.1.3	Diet - I don't know what foods are best to eat**									
		Yes	2	20.0%	28.6%					
		No	5	50.0%	71.4%					
		Missing	3	30.0%						
		Sum	10	100.0%	100.0%					
4.1.4	Diet - I eat out a lot and find it hard to eat well**									
		Yes	1	10.0%	14.3%					
		No	6	60.0%	85.7%					
		Missing	3	30.0%						
		Sum	10	100.0%	100.0%					
4.1.5	Diet - Hard to count carbs/weigh food (of T1DM patients)**									
		Yes	5	55.6%	83.3%					
		No	1	11.1%	16.7%					
		Missing	3	33.3%						
		Sum	9	100.0%	100.0%					

** of patients who have difficulties following recommended diet

SECTION 5. PHYSICAL ACTIVITY (PAEDIATRICS)

Item	Field	Category	Total	%	Relative %*	Median	Mean	SD	Min	Max
5.1	Moderate or vigorous intensity physical activity									
		150 mins/week or more	19	4.6%	39.6%					
		Less than 150 mins/week	17	4.1%	35.4%					
		Rarely/never	12	2.9%	25.0%					
		Missing	367	88.4%						
		Sum	415	100.0%	100.0%					
5.2	Muscle strengthening									
		Yes	12	2.9%	27.9%					
		No	31	7.5%	72.1%					
		Missing	372	89.6%						
		Sum	415	100%	100%					

*Relative % = % of the total excluding the missing values

5. MISSING DATA (ADULTS)

Table 5.1 Overall missing data (Adults)

	Amount of missing data in variables					
	0-5%	6-10%	11-15%	16-20%	21-40%	>40%
Proportion of variables with missing data*	28.9%	34.4%	28.9%	2.3%	2.3%	3.1%

*Relates to the proportion of variables/fields according to the amount of missing data in each variable, e.g. 28.9% of variables had 5% or less of missing data.

Table 5.2 Missing data by field (Adults)

Item no.	Clinical Parameters	2022 (n=4641)		2021 (n=4484)		2019 (n=6116)	
		n	%	n	%	n	%
	Consultation method	537	**11.6**	NA	**NA**	NA	**NA**
Demographics							
1.1	Date of birth	1	**0.0**	0	**0.0**	0	**0.0**
1.2	Sex	13	**0.3**	49	**1.1**	77	**1.3**
1.2.1	Currently pregnant (females aged 18-55 years)	123	**2.7**	17	**0.4**	78	**1.3**
1.3	Date of visit	0	**0.0**	0	**0.0**	0	**0.0**
1.4	Initial visit	63	**1.4**	124	**2.8**	82	**1.3**
1.5	Aboriginal/Torres Strait Islander	381	**8.2**	86	**1.9**	394	**6.4**
1.6	Interpreter required	476	**10.3**	NA	**NA**	NA	**NA**
1.7	NDSS	510	**11.0**	190	**4.2**	612	**10.0**
1.8	Country of birth	461	**9.9**	89	**2.0**	277	**4.5**
1.9	DVA	494	**10.6**	157	**3.5**	605	**9.9**
Diabetes type and management							
2.1	Year of diagnosis	121	**2.6**	126	**2.8**	127	**2.1**
2.2	Type of diabetes	47	**1.0**	19	**0.4**	26	**0.4**
2.3	Blood glucose monitoring	386	**8.3**	558	**12.4**	558	**9.1**
2.3.1	Finger prick - check as often as recommended	74	**1.6**	NA	**NA**	NA	**NA**
2.3.2	Finger prick - Number of times a day	58	**1.2**	NA	**NA**	NA	**NA**
2.3.3	Flash/CGM - Proportion of time using sensors	41	**0.9**	NA	**NA**	NA	**NA**
2.4	Management method	86	**1.9**	48	**1.1**	55	**0.9**
2.4.1	Insulin duration	300	**6.5**	302	**6.8**	301	**4.9**
2.4.2	Insulin mode	100	**2.2**	29	**0.6**	63	**1.0**
Height, weight and blood pressure							
3.1	Weight	352	**2.8**	254	**5.7**	193	**3.2**
	Weight - self-reported	128	**2.8**	NA	**NA**	NA	**NA**
3.2	Height	607	**13.1**	310	**6.9**	504	**8.2**
	Height - self-reported	134	**2.9**	NA	**NA**	NA	**NA**
3.3	Blood pressure - systolic	894	**19.3**	618	**13.8**	219	**3.6**
	Blood pressure - diastolic	894	**19.3**	625	**13.9**	219	**3.6**
3.4	On anti-hypertensive treatment	365	**7.9**	68	**1.5**	34	**0.6**
3.4.1	Anti-hypertensive medications	13	**0.3**	0	**0.0**	0	**0.0**
Medications and lipids							
4.1	Aspirin	367	**7.9**	18	**0.4**	14	**0.2**
4.2	Other anti-platelets	377	**8.1**	34	**0.8**	21	**0.3**
4.3	Anti-coagulants	379	**8.2**	33	**0.7**	22	**0.4**
4.4	On lipid modifying therapy	336	**7.2**	14	**0.3**	16	**0.3**

Item no.	Clinical Parameters	2022 (n=4641)		2021 (n=4484)		2019 (n=6116)	
		n	%	n	%	n	%
4.4.1	On lipid modifying therapy - Statin	7	**0.2**	8	**0.2**	5	**0.1**
4.4.2	On lipid modifying therapy - Fibrate	81	**1.7**	66	**1.5**	55	**0.9**
4.4.3	On lipid modifying therapy - Ezetimibe	79	**1.7**	73	**1.6**	58	**0.9**
4.4.4	On lipid modifying therapy - Fish oil	84	**1.8**	75	**1.7**	63	**1.0**
4.4.5	On lipid modifying therapy - Evolocumab	134	**2.9**	NA	**NA**	NA	**NA**
4.4.6	On lipid modifying therapy - Other	143	**3.1**	NA	**NA**	NA	**NA**
4.5	Lipids measured	0	**0.0**	0	**0.0**	16	**0.3**
4.5.1	Lipids measured - Total cholesterol	23	**0.5**	11	**0.2**	48	**0.8**
4.5.2	Lipids measured - LDL cholesterol	441	**9.5**	437	**9.7**	674	**11.0**
4.5.3	Lipids measured - HDL cholesterol	395	**8.5**	390	**8.7**	563	**9.2**
4.5.4	Lipids measured - Triglycerides	69	**1.5**	104	**2.3**	173	**2.8**
4.5.5	Lipids measured - Fasting lipids	117	**2.5**	163	**3.6**	19	**0.3**
Renal function and blood glucose control							
5.1	HbA_{1c} (%)	803	**17.3**	305	**6.8**	416	**6.8**
5.1.1	HbA_{1c} test date (%)	80	**1.7**	NA	**NA**	NA	**NA**
5.2	eGFR	1092	**23.5**	700	**15.6**	974	**15.9**
5.3	Serum creatinine	1193	**25.7**	662	**14.8**	931	**15.2**
5.4a	Urinary albumin result	2385	**51.4**	1872	**41.7**	2368	**38.7**
5.4b	Urinary protein result	4104	**88.4**	NA	**NA**	NA	**NA**
Diabetes related eye and foot diseases							
6.1	Retinopathy - last 12 months	354	**7.6**	92	**2.1**	75	**1.2**
	Retinopathy - previous	463	**10.0**	NA	**NA**	NA	**NA**
6.2	Treatment for retinopathy - last 12 months	372	**8.0**	185	**4.1**	88	**1.4**
	Treatment for retinopathy - previous	470	**10.1**	NA	**NA**	NA	**NA**
6.3	Right or left cataract - last 12 months	358	**7.7**	96	**2.1**	91	**1.5**
	Right or left cataract - previous	462	**10.0**	NA	**NA**	NA	**NA**
6.4	Peripheral neuropathy - last 12 months	339	**7.3**	45	**1.0**	33	**0.5**
	Peripheral neuropathy - previous	465	**10.0**	118	**2.6**	171	**2.8**
6.5	Foot ulceration - last 12 months	330	**7.1**	48	**1.1**	28	**0.5**
	Foot ulceration - previous	394	**8.5**	77	**1.7**	78	**1.3**
6.6	Peripheral vascular disease - last 12 months	338	**7.3**	55	**1.2**	32	**0.5**
	Peripheral vascular disease - previous	473	**10.2**	127	**2.8**	173	**2.8**
6.7	Lower limb amputation - last 12 months	331	**7.1**	122	**2.7**	31	**0.5**
6.7.1	Lower limb amputation - last 12 months - minor/major	2	**2.6**	3	**3.9**	1	**0.6**
	Lower limb amputation - previous	457	**9.8**	726	**16.2**	170	**2.8**
6.7.2	Lower limb amputation - previous - minor/major	2	**1.8**	8	**10.5**	2	**1.2**
Complications/events/comorbidities							
7.1	Stroke - last 12 months	310	**6.7**	37	**0.8**	14	**0.2**
	Stroke - previous	422	**9.1**	112	**2.5**	166	**2.7**
7.2	Myocardial infarction - last 12 months	310	**6.7**	44	**1.0**	17	**0.3**
	Myocardial infarction - previous	420	**9.0**	109	**2.4**	159	**2.6**
7.3	CABG/Angioplasty - last 12 months	313	**6.7**	39	**0.9**	20	**0.3**
	CABG/Angioplasty - previous	420	**9.0**	107	**2.4**	159	**2.6**
7.4	Congestive cardiac failure - last 12 months	436	**9.4**	168	**3.7**	493	**8.1**
	Congestive cardiac failure - previous	484	**10.4**	193	**4.3**	550	**9.0**
7.5	End stage renal disease - last 12 months	314	**6.8**	38	**0.8**	12	**0.2**
	End stage renal disease - previous	423	**9.1**	112	**2.5**	162	**2.6**

Item no.	Clinical Parameters	2022 (n=4641)		2021 (n=4484)		2019 (n=6116)	
		n	%	n	%	n	%
7.6	Blindness - last 12 months	391	**8.4**	91	**2.0**	106	**1.7**
	Blindness - previous	473	**10.2**	112	**2.5**	164	**2.7**
7.7	Sexual dysfunction - last 12 months	488	**10.5**	197	**4.4**	128	**2.1**
	Sexual dysfunction - previous	557	**12.0**	255	**5.7**	233	**3.8**
7.8	Dementia - last 12 months	436	**9.4**	175	**3.9**	493	**8.1**
	Dementia - previous	477	**10.3**	185	**4.1**	550	**9.0**
7.9	Depression - last 12 months	438	**9.4**	NA	**NA**	NA	**NA**
	Depression - previous	471	**10.1**	NA	**NA**	NA	**NA**
7.10	Malignancy - last 12 months	436	**9.4**	246	**5.5**	489	**8.0**
	Malignancy - previous	478	**10.3**	NA	**NA**	NA	**NA**
7.11	Diabetic ketoacidosis - last 12 months	407	**8.8**	167	**3.7**	105	**1.7**
	Diabetic ketoacidosis - previous	441	**9.5**	181	**4.0**	171	**2.8**
7.12	Hyperosmolar hyperglycaemic state - last 12 months	417	**9.0**	173	**3.9**	109	**1.8**
	Hyperosmolar hyperglycaemic state - previous	463	**10.0**	190	**4.2**	174	**2.8**
7.13	Severe hypoglycaemia - last 12 months	375	**8.1**	60	**1.3**	125	**2.0**
	Severe hypoglycaemia - last 12 months - No. of episodes	12	**6.6**	14	**7.0**	5	**1.4**
	Severe hypoglycaemia - previous	490	**10.6**	210	**4.7**	567	**9.3**
7.14	COVID-19 - last 12 months	552	**11.9**	NA	**NA**	NA	**NA**
	COVID-19 - last 12 months - hospital admission required	8	**1.0**	NA	**NA**	NA	**NA**
	COVID-19 - previous	632	**13.6**	NA	**NA**	NA	**NA**
	COVID-19 - previous - hospital admission required	1	**1.6**	NA	**NA**	NA	**NA**
7.15	Liver disease	486	**10.5**	271	**6.0**	591	**9.7**
Mental Health Screening							
8.1	Screened for depression	426	**9.2**	NA	**NA**	NA	**NA**
8.2	Screened for anxiety	427	**9.2**	NA	**NA**	NA	**NA**
8.3	Screened for diabetes distress	428	**9.2**	NA	**NA**	NA	**NA**
PATIENT HEALTH & WELL-BEING QUESTIONNAIRE							
Smoking & Vaccination Status							
1.1	Currently smoke tobacco	508	**10.9**	NA	**NA**	NA	**NA**
1.1.1	Previously smoked tobacco (of patients who don't currently smoke)	1195	**29.7**	NA	**NA**	NA	**NA**
1.2	COVID-19 vaccination in the last 12 months	648	**14.0**	NA	**NA**	NA	**NA**
1.2.1	Number of COVID-19 vaccine doses	18	**0.5**	NA	**NA**	NA	**NA**
1.2.2	Date of last COVID-19 vaccine	1493	**40.1**	NA	**NA**	NA	**NA**
1.3	Flu (influenza) vaccination in the last 12 months	673	**14.5**	NA	**NA**	NA	**NA**
1.4	Pneumococcal vaccination in the last 12 months	692	**14.9**	NA	**NA**	NA	**NA**
Health Professional Attendances							
2.1	Endocrinologist	538	**11.6**	NA	**NA**	NA	**NA**
2.2	Diabetes Educator	560	**12.1**	NA	**NA**	NA	**NA**
2.3	Dietitian	587	**12.6**	NA	**NA**	NA	**NA**
2.4	Podiatrist	565	**12.2**	NA	**NA**	NA	**NA**
2.5	Ophthalmologist	575	**12.4**	NA	**NA**	NA	**NA**
2.6	Optometrist	567	**12.2**	NA	**NA**	NA	**NA**
2.7	Psychologist	592	**12.8**	NA	**NA**	NA	**NA**
2.8	Social Worker	594	**12.8**	NA	**NA**	NA	**NA**
2.9	Dentist	583	**12.6**	NA	**NA**	NA	**NA**

Item no.	Clinical Parameters	2022 (n=4641)		2021 (n=4484)		2019 (n=6116)	
		n	%	n	%	n	%
2.10	Exercise Physiologist/Physiotherapist	538	**11.6**	NA	**NA**	NA	**NA**
Medication Use							
3.1	Ever forget to take medications	623	**13.4**	NA	**NA**	NA	**NA**
3.1.1	Number of times per week (of those who forget to take medications)	18	**1.9**	NA	**NA**	NA	**NA**
Patient Self-Care Practices							
4.1	Difficulties following recommended diet	629	**13.6**	NA	**NA**	NA	**NA**
4.1.1	Don't have enough time to prepare healthy meals	29	**2.5**	NA	**NA**	NA	**NA**
4.1.2	Costs too much to eat well	33	**2.8**	NA	**NA**	NA	**NA**
4.1.3	Don't know what foods are best to eat	32	**2.8**	NA	**NA**	NA	**NA**
4.1.4	Eat out a lot and find it hard to eat well	32	**2.8**	NA	**NA**	NA	**NA**
4.1.5	(T1DM) Too hard to count carbs/weigh food	11	**3.3**	NA	**NA**	NA	**NA**
Physical Activity							
5.1	Moderate/vigorous intensity physical activity	625	**13.5**	NA	**NA**	NA	**NA**
5.2	Muscle strengthening exercise	661	**14.2**	NA	**NA**	NA	**NA**

Mean age, BMI and median duration by diabetes type

Diabetes type	Age (years)					BMI (kg/m^2)					Duration (years)		
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Median	IQR
T1DM	1406	44.2	17.9	18.0	91.0	1252	27.9	6.0	6.5	54.8	1384	17.4	7.4 - 30.5
T2DM	2935	63.8	13.5	19.8	100.8	2596	33.2	7.9	16.0	97.7	2897	12.4	5.3 - 20.5
Don't know	136	53.0	19.5	18.6	95.9	55	29.4	7.5	17.5	50.8	122	2.3	1.3 - 2.8
Other	116	53.6	15.5	18.5	79.0	98	27.2	7.3	16.7	59.2	114	5.4	1.4 - 14.2
Unstated	47	51.8	18.1	20.5	80.0	16	30.0	6.7	20.7	51.3	3	10.4	6.9 - 16.4
Total	**4640**	**57.2**	**17.7**	**18.0**	**100.8**	**4017**	**31.3**	**7.7**	**6.5**	**97.7**	**4520**	**12.5**	**5.4 - 22.4**



















X-axis: All sites (Descending order)

BMI by diabetes type

Diabetes type	<25 (kg/m^2)			25-30 (kg/m^2)			≥30 (kg/m^2)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	445	35.5	54.1	439	35.1	38.4	368	29.4	18.0	**1252**	**31.2**
T2DM	316	12.2	38.4	652	25.1	57.0	1628	62.7	79.4	**2596**	**64.6**
Don't know	18	32.7	2.2	17	30.9	1.5	20	36.4	1.0	**55**	**1.4**
Other	41	41.8	5.0	30	30.6	2.6	27	27.6	1.3	**98**	**2.4**
Unstated	3	18.8	0.4	6	37.5	0.5	7	43.8	0.3	**16**	**0.4**
Total	**823**	**20.5**		**1144**	**28.5**		**2050**	**51.0**		4017	



















X-axis: All sites (Descending order)

Sex by diabetes type

Diabetes type	Males			Females			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	711	50.6	28.2	694	49.4	33.0	**1405**	**30.4**
T2DM	1647	56.2	65.3	1285	43.8	61.0	**2932**	**63.4**
Don't know	78	57.4	3.1	58	42.6	2.8	**136**	**2.9**
Other	67	57.8	2.7	49	42.2	2.3	**116**	**2.5**
Unstated	19	48.7	0.8	20	51.3	0.9	**39**	**0.8**
Total	**2522**	**54.5**		**2106**	**45.5**		4628	

Currently pregnant* by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	31	7.1	73.8	408	92.9	54.6	**439**	**55.6**
T2DM	11	3.4	26.2	313	96.6	41.9	**324**	**41.1**
Don't know	0	0.0	0.0	2	100.0	0.3	**2**	**0.3**
Other	0	0.0	0.0	21	100.0	2.8	**21**	**2.7**
Unstated	0	0.0	0.0	3	100.0	0.4	**3**	**0.4**
Total	**42**	**5.3**		**747**	**94.7**		789	

* females aged 18-55 years

Initial visit by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	137	9.9	16.8	1252	90.1	33.3	**1389**	**30.3**
T2DM	652	22.5	79.8	2248	77.5	59.8	**2900**	**63.3**
Don't know	11	8.1	1.3	125	91.9	3.3	**136**	**3.0**
Other	15	13.2	1.8	99	86.8	2.6	**114**	**2.5**
Unstated	2	5.1	0.2	37	94.9	1.0	**39**	**0.9**
Total	**817**	**17.8**		**3761**	**82.2**		4578	

Interpreter required by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	15	1.2	12.3	1233	98.8	30.5	**1248**	**27.3**
T2DM	104	3.7	85.2	2692	96.3	66.6	**2796**	**61.1**
Don't know	0	0.0	0.0	11	100.0	0.3	**11**	**0.2**
Other	3	3.1	2.5	95	96.9	2.3	**98**	**2.1**
Unstated	0	0.0	0.0	12	100.0	0.3	**12**	**0.3**
Total	**122**	**2.9**		**4043**	**97.1**		4165	

Aborignal/Torres Strait Islander status by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	36	2.8	11.2	1233	97.2	31.3	**1269**	**29.8**
T2DM	278	9.7	86.3	2588	90.3	65.7	**2866**	**67.3**
Don't know	0	0.0	0.0	11	100.0	0.3	**11**	**0.3**
Other	8	7.8	2.5	94	92.2	2.4	**102**	**2.4**
Unstated	0	0.0	0.0	12	100.0	0.3	**12**	**0.3**
Total	**322**	**7.6**		**3938**	**92.4**		4260	

Australian born by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	1033	82.4	33.6	221	17.6	19.9	**1254**	**30.0**
T2DM	1955	69.8	63.7	844	30.2	76.1	**2799**	**67.0**
Don't know	7	63.6	0.2	4	36.4	0.4	**11**	**0.3**
Other	58	60.4	1.9	38	39.6	3.4	**96**	**2.3**
Unstated	18	90.0	0.6	2	10.0	0.2	**20**	**0.5**
Total	**3071**	**73.5**		**1109**	**26.5**		4180	

NDSS by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	1194	96.1	32.7	49	3.9	10.3	**1243**	**30.1**
T2DM	2368	85.4	64.8	404	14.6	85.1	**2772**	**67.1**
Don't know	8	80.0	0.2	2	20.0	0	**10**	**0.2**
Other	84	87.5	2.3	12	12.5	2.5	**96**	**2.3**
Unstated	2	20.0	0.1	8	80.0	2	**10**	**0.2**
Total	**3656**	**88.5**		**475**	**11.5**		4131	

DVA by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	17	1.4	22.7	1228	98.6	30.2	**1245**	**30.0**
T2DM	58	2.1	77.3	2728	97.9	67.0	**2786**	**67.2**
Don't know	0	0.0	0.0	10	100.0	0	**10**	**0.2**
Other	0	0.0	0.0	96	100.0	2.4	**96**	**2.3**
Unstated	0	0.0	0.0	10	100.0	0	**10**	**0.2**
Total	**75**	**1.8**		**4072**	**98.2**		4147	

Methods of blood glucose monitoring*

Diabetes type	None			Finger prick			Continuous			Flash			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	8	0.7	1.1	670	61.7	21.9	408	37.6	90.3	352	32.4	79.8	**1086**	**27.2**
T2DM	461	16.5	66.0	2301	82.4	75.3	29	1.0	6.4	70	2.5	15.9	**2791**	**69.8**
Don't know	2	10.5	0.3	8	42.1	0.3	9	47.4	2.0	0	0.0	0.0	**19**	**0.5**
Other	9	10.5	1.3	72	83.7	2.4	5	5.8	1.1	17	19.8	3.9	**86**	**2.2**
Unstated	10	58.8	1.4	6	35.3	0.2	1	5.9	0.2	2	11.8	0.5	**17**	**0.4**
Total	**490**	**12.3**		**3057**	**76.4**		**452**	**11.3**		**441**	**11.0**		3999	

* multiple methods reported by some patients



















X-axis: All sites (Descending order)

Proportion of time using blood glucose monitoring sensors*

Diabetes type	<50%			50-75%			>75-100%			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	84	11.6	12.0	85	11.7	87.6	558	76.8	87.5	727	18.2
T2DM	23	25.3	3.3	8	8.8	8.2	60	65.9	9.4	91	2.3
Don't know	3	33.3	0.4	1	11.1	1.0	5	55.6	0.8	9	0.2
Other	3	14.3	0.4	3	14.3	3.1	15	71.4	2.4	21	0.5
Unstated	NA	NA	NA	NA	NA	NA	NA	NA	NA	0	0.0
Total	**113**	**13.3**		**97**	**11.4**		**638**	**75.2**		**848**	

* of patients using flash/continuous glucose monitoring



















X-axis: All sites (Descending order)

Smoking status by diabetes type

Diabetes type	Current smoker			Past smoker			Never smoked			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	187	15.4	30.5	262	21.6	20.8	766	63.0	35.0	**1215**	**29.9**
T2DM	405	14.9	66.0	963	35.4	76.5	1355	49.8	62.0	**2723**	**67.1**
Don't know	4	36.4	0.7	2	18.2	0.2	5	45.5	0.2	**11**	**0.3**
Other	14	15.1	2.3	31	33.3	2.5	48	51.6	2.2	**93**	**2.3**
Unstated	4	22.2	0.7	1	5.6	0.1	13	72.2	0.6	**18**	**0.4**
Total	**614**	**15.1**		**1259**	**31.0**		**2187**	**53.9**		4060	



















X-axis: All sites (Descending order)

Age by blood pressure level

Age	<130/80		≥130/80		<140/90		≥140/90	
	n	C%	n	C%	n	C%	n	C%
≤60 years	605	50.8	1130	44.2	1209	50.6	526	38.8
>60 years	587	49.2	1425	55.8	1182	49.4	830	61.2
Total	**1192**		**2555**		**2391**		**1356**	









X-axis: All sites (Descending order)

Treatment by diabetes type

Diabetes type	Diet only			Tablets			Insulin			Insulin & tablets			Injectables		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	0	0.0	0.0	0	0.0	0.0	1240	88.1	81.7	137	9.7	13.6	0	0.0	0.0
T2DM	140	4.8	94.6	793	27.0	96.7	192	6.5	12.7	821	28.0	81.5	15	0.5	93.8
Don't know	1	0.7	0.7	15	11.0	1.8	33	24.3	2.2	7	5.1	0.7	1	0.7	6.3
Other	7	6.0	4.7	12	10.3	1.5	43	37.1	2.8	37	31.9	3.7	0	0.0	0.0
Unstated	0	0.0	0.0	0	0.0	0.0	9	19.1	0.6	5	10.6	0.5	0	0.0	0.0
Total	**148**	**3.2**		**820**	**17.7**		**1517**	**32.7**		**1007**	**21.7**		**16**	**0.3**	

Diabetes type	Injectables & insulin (not graphed)			Injectables & tablets			Injectables, tablets & insulin			Unstated (not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	0	0.0	0.0	0	0.0	0.0	20	1.4	23.5	10	0.7	2.0	**1407**	**30.3**
T2DM	10	0.3	8.4	417	14.2	98.1	63	2.1	74.1	484	16.5	96.0	**2935**	**63.2**
Don't know	68	50.0	57.1	6	4.4	1.4	2	1.5	2.4	3	2.2	0.6	**136**	**2.9**
Other	8	6.9	6.7	2	1.7	0.5	0	0.0	0.0	7	6.0	1.4	**116**	**2.5**
Unstated	33	70.2	27.7	0	0.0	0.0	0	0.0	0.0	0	0.0	0.0	**47**	**1.0**
Total	**119**	**2.6**		**425**	**9.2**		**85**	**1.8**		**504**	**10.9**		4641	



X-axis: All sites (Descending order)













X-axis: All sites (Descending order)

Modes of insulin by diabetes type*

Diabetes type	Basal			Basal bolus			Pump			Pre-mixed insulin			Hybrid System		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	188	12.3	26.9	907	59.3	63.1	291	19.0	98.3	83	5.4	10.4	60	3.9	100.0
T2DM	465	29.4	66.6	440	27.8	30.6	4	0.3	1.4	675	42.6	84.9	0	0.0	0.0
Don't know	24	38.7	3.4	27	43.5	1.9	0	0.0	0.0	11	17.7	1.4	0	0.0	0.0
Other	14	14.9	2.0	55	58.5	3.8	1	1.1	0.3	24	25.5	3.0	0	0.0	0.0
Unstated	7	38.9	1.0	9	50.0	0.6	0	0.0	0.0	2	11.1	0.3	0	0.0	0.0
Total	**698**	**21.2**		**1438**	**43.7**		**296**	**9.0**		**795**	**24.2**		**60**	**1.8**	

* patients taking insulin (multiple modes of insulin were reported for some patients)













Diabetes type	Total	
	n	%
T1DM	1529	46.5
T2DM	1584	48.2
Don't know	62	1.9
Other	94	2.9
Unstated	18	0.5
Total	**3287**	

X-axis: All sites (Descending order)



















X-axis: All sites (Descending order)

HbA1c (%) by diabetes type

Diabetes type	n	Mean	SD	Min	Max
T1DM	1156	8.4	1.8	4.9	17.5
T2DM	2567	8.3	1.9	4.2	18.7
Don't know	10	10.4	2.7	6.0	13.8
Other	98	8.4	2.3	4.9	17.2
Unstated	7	7.9	1.4	6.6	10.1
Total	**3838**	**8.4**	**1.9**	**4.2**	**18.7**







X-axis: All sites (Descending order)

HbA1c (%) and initial visit by diabetes type

Diabetes type	HbA1c when initial visit = No				
	n	Mean	SD	Min	Max
T1DM	1022	8.3	1.7	4.9	17.5
T2DM	2032	8.1	1.8	4.2	17.3
Don't know	6	11.5	2.4	4.9	13.8
Other	84	8.3	2.2	4.9	17.2
Unstated	2	8.3	1.5	4.9	10.1
Total	**3146**	**8.2**	**1.8**	**4.2**	**17.5**







X-axis: All sites (Descending order)

Mean total cholesterol, HDL cholesterol and median triglycerides by diabetes type

Diabetes type	Total cholesterol					HDL					Triglycerides		
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Median	IQR
T1DM	775	4.6	1.2	1.5	14.8	657	1.5	0.5	0.4	4.4	752	1.1	0.8 - 1.6
T2DM	1963	4.2	1.6	1.9	47.0	1723	1.1	0.4	0.1	4.0	1941	1.8	1.3 - 2.7
Don't know	5	5.0	2.1	3.5	8.7	5	1.1	0.2	0.9	1.4	5	1.4	1.0 - 1.4
Other	69	4.4	1.2	1.3	8.5	56	1.2	0.4	0.3	2.5	69	1.4	1.0 - 1.9
Unstated	2	4.5	0.9	3.8	5.1	1	1.5	NA	1.5	1.5	1	1.0	1.0 - 1.0
Total	**2814**	**4.3**	**1.5**	**1.3**	**47.0**	**2442**	**1.2**	**0.4**	**0.1**	**4.4**	**2768**	**1.6**	**1.1 - 2.4**



X-axis: All sites (Descending order)

Mean total cholesterol, HDL cholesterol and median triglycerides (fasting) by diabetes type

Diabetes type	Total cholesterol					HDL					Triglycerides		
	n	Mean	SD	Min	Max	n	Mean	SD	Min	Max	n	Median	IQR
T1DM	560	4.6	1.2	1.5	14.8	479	1.5	0.4	0.4	4.4	547	1.0	0.8 - 1.6
T2DM	1567	4.2	1.7	1.9	47.0	1381	1.1	0.4	0.1	4.0	1550	1.8	1.3 - 2.6
Don't know	2	6.2	3.5	3.7	8.7	2	1.1	0.1	1.0	1.1	2	2.4	1.7 - 3.1
Other	48	4.4	1.0	2.6	6.7	41	1.3	0.4	0.6	2.5	48	1.4	1.0 - 1.8
Unstated	1	5.1	NA	5.1	5.1	1	1.5	NA	1.5	1.5	1	1.0	1.0 - 1.0
Total	**2178**	**4.3**	**1.6**	**1.5**	**47.0**	**1904**	**1.2**	**0.4**	**0.1**	**4.4**	**2148**	**1.6**	**1.1 - 2.4**



















X-axis: All sites (Descending order)

Total cholesterol by diabetes type

Diabetes type	<4.0 (mmol/L)			≥4.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	234	30.2	19.0	541	69.8	34.2	**775**	**27.5**
T2DM	969	49.4	78.7	994	50.6	62.8	**1963**	**69.8**
Don't know	2	40.0	0.2	3	60.0	0.2	**5**	**0.2**
Other	25	36.2	2.0	44	63.8	2.8	**69**	**2.5**
Unstated	1	50.0	0.1	1	50.0	0.1	**2**	**0.1**
Total	**1231**	**43.7**		**1583**	**56.3**		2814	













X-axis: All sites (Descending order)

Total cholesterol (fasting) by diabetes type

Diabetes type	<4.0 (mmol/L)			≥4.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	173	30.9	17.6	387	69.1	32.4	**560**	**25.7**
T2DM	791	50.5	80.5	776	49.5	64.9	**1567**	**71.9**
Don't know	1	50.0	0.1	1	50.0	0.1	**2**	**0.1**
Other	17	35.4	1.7	31	64.6	2.6	**48**	**2.2**
Unstated	0	0.0	0.0	1	100.0	0.1	**1**	**0.0**
Total	**982**	**45.1**		**1196**	**54.9**		2178	













X-axis: All sites (Descending order)

HDL cholesterol by diabetes type

Diabetes type	<1.0 (mmol/L)			≥1.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	60	9.1	8.7	597	90.9	34.1	**657**	**26.9**
T2DM	618	35.9	89.7	1105	64.1	63.0	**1723**	**70.6**
Don't know	1	20.0	0.1	4	80.0	0.2	**5**	**0.2**
Other	10	17.9	1.5	46	82.1	2.6	**56**	**2.3**
Unstated	0	0.0	0.0	1	100.0	0.1	**1**	**0.0**
Total	**689**	**28.2**		**1753**	**71.8**		**2442**	













X-axis: All sites (Descending order)

HDL cholesterol (fasting) by diabetes type

Diabetes type	<1.0 (mmol/L)			≥1.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	44	9.2	8.3	435	90.8	31.6	**479**	**25.2**
T2DM	478	34.6	90.7	903	65.4	65.6	**1381**	**72.5**
Don't know	0	0.0	0.0	2	100.0	0.1	**2**	**0.1**
Other	5	12.2	0.9	36	87.8	2.6	**41**	**2.2**
Unstated	0	0.0	0.0	1	100.0	0.1	**1**	**0.1**
Total	**527**	**27.7**		**1377**	**72.3**		1904	













X-axis: All sites (Descending order)

Triglycerides by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	623	82.8	35.8	129	17.2	12.5	**752**	**27.2**
T2DM	1057	54.5	60.8	884	45.5	85.8	**1941**	**70.1**
Don't know	4	80.0	0.2	1	20.0	0.1	**5**	**0.2**
Other	53	76.8	3.0	16	23.2	1.6	**69**	**2.5**
Unstated	1	100.0	0.1	0	0.0	0.0	**1**	**0.0**
Total	**1738**	**62.8**		**1030**	**37.2**		2768	













X-axis: All sites (Descending order)

Triglycerides (fasting) by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	453	82.8	33.2	94	17.2	12.0	**547**	**25.5**
T2DM	872	56.3	63.8	678	43.7	86.7	**1550**	**72.2**
Don't know	1	50.0	0.1	1	50.0	0.1	**2**	**0.1**
Other	39	81.3	2.9	9	18.8	1.2	**48**	**2.2**
Unstated	1	100.0	0.1	0	0.0	0.0	**1**	**0.0**
Total	**1366**	**63.6**		**782**	**36.4**		2148	













X-axis: All sites (Descending order)

Mean LDL cholesterol by diabetes type

Diabetes type	LDL				
	n	Mean	SD	Min	Max
T1DM	659	2.5	1.0	0.3	14.4
T2DM	1674	2.1	1.0	0.1	8.6
Don't know	4	3.3	1.8	2.1	5.9
Other	56	2.4	1.0	0.4	5.8
Unstated	3	2.2	0.8	1.7	3.1
Total	**2396**	**2.2**	**1.0**	**0.1**	**14.4**







X-axis: All sites (Descending order)

Mean LDL cholesterol (fasting) by diabetes type

Diabetes type	LDL				
	n	Mean	SD	Min	Max
T1DM	484	2.5	1.1	0.3	14.4
T2DM	1353	2.1	1.0	0.1	8.6
Don't know	2	4.1	2.5	2.3	5.9
Other	41	2.5	0.9	0.4	4.1
Unstated	1	3.1	NA	3.1	3.1
Total	**1881**	**2.2**	**1.0**	**0.1**	**14.4**







X-axis: All sites (Descending order)

LDL cholesterol by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	190	28.8	17.5	469	71.2	35.7	**659**	**27.5**
T2DM	871	52.0	80.4	803	48.0	61.2	**1674**	**69.9**
Don't know	0	0.0	0.0	4	100.0	0.3	**4**	**0.2**
Other	21	37.5	1.9	35	62.5	2.7	**56**	**2.3**
Unstated	2	66.7	0.2	1	33.3	0.1	**3**	**0.1**
Total	**1084**	**45.2**		**1312**	**54.8**		2396	













X-axis: All sites (Descending order)

LDL cholesterol (fasting) by diabetes type

Diabetes type	<2.0 (mmol/L)			≥2.0 (mmol/L)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	137	28.3	16.1	347	71.7	33.7	**484**	**25.7**
T2DM	703	52.0	82.5	650	48.0	63.2	**1353**	**71.9**
Don't know	0	0.0	0.0	2	100.0	0.2	**2**	**0.1**
Other	12	29.3	1.4	29	70.7	2.8	**41**	**2.2**
Unstated	0	0.0	0.0	1	100.0	0.1	**1**	**0.1**
Total	**852**	**45.3**		**1029**	**54.7**		1881	













X-axis: All sites (Descending order)

Diabetic ketoacidosis (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	99	7.8	68.8	1171	92.2	28.6	**1270**	**30.0**
T2DM	30	1.1	20.8	2788	98.9	68.2	**2818**	**66.6**
Don't know	8	29.6	5.6	19	70.4	0.5	**27**	**0.6**
Other	7	7.0	4.9	93	93.0	2.3	**100**	**2.4**
Unstated	0	0.0	0.0	19	100.0	0.5	**19**	**0.4**
Total	**144**	**3.4**		**4090**	**96.6**		4234	







X-axis: All sites (Descending order)

Hyperosmolar hyperglycaemic state (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	3	0.2	8.8	1268	99.8	30.3	1271	30.1
T2DM	30	1.1	88.2	2782	98.9	66.4	2812	66.6
Don't know	0	0.0	0.0	21	100.0	0.5	21	0.5
Other	1	1.0	2.9	100	99.0	2.4	101	2.4
Unstated	0	0.0	0.0	19	100.0	0.5	19	0.4
Total	34	0.8		4190	99.2		4224	



X-axis: All sites (Descending order)

Severe hypoglycaemia (last 12 months) by diabetes type

Diabetes type	Yes			No (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	118	9.3	65.2	1152	90.7	28.2	1270	29.8
T2DM	52	1.8	28.7	2807	98.2	68.7	2859	67.0
Don't know	4	26.7	2.2	11	73.3	0.3	15	0.4
Other	6	5.8	3.3	97	94.2	2.4	103	2.4
Unstated	1	5.3	0.6	18	94.7	0.4	19	0.4
Total	**181**	**4.2**		**4085**	**95.8**		4266	







X-axis: All sites (Descending order)

Albuminuria by diabetes type

Diabetes type	Normal to mildly increased			Moderately increased			Severely increased			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	493	70.9	36.0	157	22.6	22.6	45	6.5	16.0	**695**	**29.6**
T2DM	836	52.4	61.0	528	33.1	75.9	230	14.4	81.9	**1594**	**67.9**
Don't know	4	66.7	0.3	1	16.7	0.1	1	16.7	0.4	**6**	**0.3**
Other	34	69.4	2.5	10	20.4	1.4	5	10.2	1.8	**49**	**2.1**
Unstated	3	100.0	0.2	0	0.0	0.0	0	0.0	0.0	**3**	**0.1**
Total	**1370**	**58.4**		**696**	**29.7**		**281**	**12.0**		2347	



X-axis: All sites (Descending order)

eGFR levels by diabetes type

Diabetes type	eGFR ≥90			eGFR 60 - <90			eGFR 30 - <60		
	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	602	60.3	39.7	277	27.8	23.7	99	9.9	14.6
T2DM	862	35.3	56.9	851	34.9	72.7	568	23.3	83.8
Don't know	6	60.0	0.4	4	40.0	0.3	0	0.0	0.0
Other	44	46.8	2.9	34	36.2	2.9	11	11.7	1.6
Unstated	1	16.7	0.1	5	83.3	0.4	0	0.0	0.0
Total	**1515**	**42.7**		**1171**	**33.0**		**678**	**19.1**	

Diabetes type	eGFR 15 - <30			eGFR <15			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	15	1.5	11.5	5	0.5	9.1	**998**	**28.9**
T2DM	114	4.7	87.7	46	1.9	83.6	**2441**	**70.8**
Don't know	0	0.0	0.0	0	0.0	0.0	**10**	**0.3**
Other	1	1.1	0.8	4	4.3	7.3	**94**	**2.7**
Unstated	0	0.0	0.0	0	0.0	0.0	**6**	**0.2**
Total	**130**	**3.7**		**55**	**1.5**		3549	













X-axis: All sites (Descending order)



















X-axis: All sites (Descending order)

Serum creatinine levels by diabetes type

Diabetes type	<120 (µmol/L)			≥120 - ≤500 (µmol/L)			>500 (µmol/L)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	886	92.5	30.4	71	7.4	14.0	1	0.1	3.4	**958**	**27.8**
T2DM	1925	80.9	66.1	428	18.0	84.4	26	1.1	89.7	**2379**	**69.0**
Don't know	10	100.0	0.3	0	0.0	0.0	0	0.0	0.0	**10**	**0.3**
Other	86	89.6	3.0	8	8.3	1.6	2	2.1	6.9	**96**	**2.8**
Unstated	5	100.0	0.2	0	0.0	0.0	0	0.0	0.0	**5**	**0.1**
Total	**2912**	**84.5**		**507**	**14.7**		**29**	**0.8**		**3448**	



















X-axis: All sites (Descending order)

Number of complications by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	1057	75.1	39.2	259	18.4	19.0	91	6.5	15.6	**1407**	**30.3**
T2DM	1410	48.0	52.3	1047	35.7	76.8	478	16.3	82.1	**2935**	**63.2**
Don't know	119	87.5	4.4	12	8.8	0.9	5	3.7	0.9	**136**	**2.9**
Other	70	60.3	2.6	39	33.6	2.9	7	6.0	1.2	**116**	**2.5**
Unstated	39	83.0	1.4	7	14.9	0.5	1	2.1	0.2	**47**	**1.0**
Total	**2695**	**58.1**		**1364**	**29.4**		**582**	**12.5**		4641	



















X-axis: All sites (Descending order)

Number of cardiovascular complications* by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	1311	93.2	33.8	87	6.2	12.5	9	0.6	12.9	**1407**	**30.3**
T2DM	2287	77.9	59.0	588	20.0	84.7	60	2.0	85.7	**2935**	**63.2**
Don't know	131	96.3	3.4	5	3.7	0.7	0	0.0	0.0	**136**	**2.9**
Other	103	88.8	2.7	12	10.3	1.7	1	0.9	1.4	**116**	**2.5**
Unstated	45	95.7	1.2	2	4.3	0.3	0	0.0	0.0	**47**	**1.0**
Total	**3877**	**83.5**		**694**	**15.0**		**70**	**1.5**		4641	

*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



















X-axis: All sites (Descending order)

Number of cardiovascular complications* (current smokers) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	178	95.2	34.9	8	4.3	9.1	1	0.5	6.3	187	30.5
T2DM	311	76.8	61.0	79	19.5	89.8	15	3.7	93.8	405	66.0
Don't know	4	100.0	0.8	0	0.0	0.0	0	0.0	0.0	4	0.7
Other	13	92.9	2.5	1	7.1	1.1	0	0.0	0.0	14	2.3
Unstated	4	100.0	0.8	0	0.0	0.0	0	0.0	0.0	4	0.7
Total	**510**	**83.1**		**88**	**14.3**		**16**	**2.6**		**614**	

*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



X-axis: All sites (Descending order)

Number of cardiovascular complications* (past smokers) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	230	87.8	24.3	26	9.9	9.3	6	2.3	20.0	262	20.8
T2DM	691	71.8	72.9	248	25.8	88.3	24	2.5	80.0	963	76.5
Don't know	1	50.0	0.1	NA	NA	NA	0	0.0	0.0	2	0.2
Other	25	80.6	2.6	6	19.4	2.1	0	0.0	0.0	31	2.5
Unstated	1	100.0	0.1	0	0.0	0.0	0	0.0	0.0	1	0.1
Total	**948**	**75.3**		**281**	**22.3**		**30**	**2.4**		1259	

*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



















X-axis: All sites (Descending order)

Number of cardiovascular complications* (never smoked) by diabetes type

Diabetes type	0			1-2			≥3			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	718	93.7	38.2	46	6.0	16.1	2	0.3	9.5	766	35.0
T2DM	1103	81.4	58.6	233	17.2	81.8	19	1.4	90.5	1355	62.0
Don't know	5	100.0	0.3	0	0.0	0.0	0	0.0	0.0	5	0.2
Other	44	91.7	2.3	4	8.3	1.4	0	0.0	0.0	48	2.2
Unstated	11	84.6	0.6	2	15.4	0.7	0	0.0	0.0	13	0.6
Total	**1881**	**86.0**		**285**	**13.0**		**21**	**1.0**		2187	

*possible complications include macrovascular/microvascular complications. Occurrence of a complication, both in the past 12 months and previously, is counted only once.



















X-axis: All sites (Descending order)

ACE inhibitor use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	218	15.5	19.2	1189	84.5	33.9	**1407**	**30.3**
T2DM	881	30.0	77.7	2054	70.0	58.6	**2935**	**63.2**
Don't know	6	4.4	0.5	130	95.6	3.7	**136**	**2.9**
Other	25	21.6	2.2	91	78.4	2.6	**116**	**2.5**
Unstated	4	8.5	0.4	43	91.5	1.2	**47**	**1.0**
Total	**1134**	**24.4**		**3507**	**75.6**		4641	



X-axis: All sites (Descending order)

ARB use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	154	10.9	15.7	1253	89.1	34.2	**1407**	**30.3**
T2DM	809	27.6	82.4	2126	72.4	58.1	**2935**	**63.2**
Don't know	3	2.2	0.3	133	97.8	3.6	**136**	**2.9**
Other	14	12.1	1.4	102	87.9	2.8	**116**	**2.5**
Unstated	2	4.3	0.2	45	95.7	1.2	**47**	**1.0**
Total	**982**	**21.2**		**3659**	**78.8**		4641	













X-axis: All sites (Descending order)

Beta blocker use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	85	6.0	11.2	1322	94.0	34.0	**1407**	**30.3**
T2DM	651	22.2	86.1	2284	77.8	58.8	**2935**	**63.2**
Don't know	3	2.2	0.4	133	97.8	3.4	**136**	**2.9**
Other	15	12.9	2.0	101	87.1	2.6	**116**	**2.5**
Unstated	2	4.3	0.3	45	95.7	1.2	**47**	**1.0**
Total	**756**	**16.3**		**3885**	**83.7**		4641	













X-axis: All sites (Descending order)

Calcium channel antagonist use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	119	8.5	15.2	1288	91.5	33.4	**1407**	**30.3**
T2DM	645	22.0	82.6	2290	78.0	59.3	**2935**	**63.2**
Don't know	3	2.2	0.4	133	97.8	3.4	**136**	**2.9**
Other	12	10.3	1.5	104	89.7	2.7	**116**	**2.5**
Unstated	2	4.3	0.3	45	95.7	1.2	**47**	**1.0**
Total	**781**	**16.8**		**3860**	**83.2**		4641	













X-axis: All sites (Descending order)

Thiazide use by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	38	2.7	12.1	1369	97.3	31.6	1407	30.3
T2DM	269	9.2	85.9	2666	90.8	61.6	2935	63.2
Don't know	1	0.7	0.3	135	99.3	3.1	136	2.9
Other	4	3.4	1.3	112	96.6	2.6	116	2.5
Unstated	1	2.1	0.3	46	97.9	1.1	47	1.0
Total	**313**	**6.7**		**4328**	**93.3**		4641	













X-axis: All sites (Descending order)

Other anti-hypertensive therapy by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	33	2.3	10.6	1374	97.7	31.7	**1407**	**30.3**
T2DM	270	9.2	86.5	2665	90.8	61.6	**2935**	**63.2**
Don't know	2	1.5	0.6	134	98.5	3.1	**136**	**2.9**
Other	7	6.0	2.2	109	94.0	2.5	**116**	**2.5**
Unstated	0	0.0	0.0	47	100.0	1.1	**47**	**1.0**
Total	**312**	**6.7**		**4329**	**93.3**		4641	













X-axis: All sites (Descending order)

Lipid modifying therapy by diabetes type

Diabetes type	Yes			No			Total	
	n	R%	C%	n	R%	C%	n	%
T1DM	480	37.6	18.6	797	62.4	46.3	1277	29.7
T2DM	2037	70.5	78.9	851	29.5	49.4	2888	67.1
Don't know	10	62.5	0.4	6	37.5	0.3	16	0.4
Other	47	45.2	1.8	57	54.8	3.3	104	2.4
Unstated	8	40.0	0.3	12	60.0	0.7	20	0.5
Total	2582	60.0		1723	40.0		4305	













X-axis: All sites (Descending order)

Statin* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	451	94.4	18.7	24	5.0	16.3	3	0.6	18.8	**478**	**18.6**
T2DM	1901	93.5	78.8	119	5.9	81.0	13	0.6	81.3	**2033**	**79.0**
Don't know	8	88.9	0.3	1	11.1	0.7	0	0.0	0.0	**9**	**0.3**
Other	44	93.6	1.8	3	6.4	2.0	0	0.0	0.0	**47**	**1.8**
Unstated	8	100.0	0.3	0	0.0	0.0	0	0.0	0.0	**8**	**0.3**
Total	**2412**	**93.7**		**147**	**5.7**		**16**	**0.6**		2575	

*of patients who take lipid modifying therapy



X-axis: All sites (Descending order)

Fibrate* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	49	10.7	15.9	406	89.0	18.6	1	0.2	14.3	**456**	**18.2**
T2DM	252	12.7	81.8	1734	87.0	79.3	6	0.3	85.7	**1992**	**79.6**
Don't know	2	40.0	0.6	3	60.0	0.1	0	0.0	0.0	**5**	**0.2**
Other	5	11.1	1.6	40	88.9	1.8	0	0.0	0.0	**45**	**1.8**
Unstated	0	0.0	0.0	3	100.0	0.1	0	0.0	0.0	**3**	**0.1**
Total	**308**	**12.3**		**2186**	**87.4**		**7**	**0.3**		2501	

*of patients who take lipid modifying therapy



X-axis: All sites (Descending order)

Ezetimibe* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	54	11.8	16.1	403	88.0	18.6	1	0.2	14.3	**458**	**18.3**
T2DM	275	13.8	82.1	1710	85.9	79.1	6	0.3	85.7	**1991**	**79.6**
Don't know	0	0.0	0.0	4	100.0	0.2	0	0.0	0.0	**4**	**0.2**
Other	5	10.9	1.5	41	89.1	1.9	0	0.0	0.0	**46**	**1.8**
Unstated	1	25.0	0.3	3	75.0	0.1	0	0.0	0.0	**4**	**0.2**
Total	**335**	**13.4**		**2161**	**86.3**		**7**	**0.3**		2503	

*of patients who take lipid modifying therapy













X-axis: All sites (Descending order)

Fish oil* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	20	4.4	15.6	436	95.6	18.4	0	0.0	0.0	**456**	**18.2**
T2DM	102	5.1	79.7	1884	94.7	79.6	4	0.2	100.0	**1990**	**79.6**
Don't know	1	25.0	0.8	3	75.0	0.1	0	0.0	0.0	**4**	**0.2**
Other	5	11.1	3.9	40	88.9	1.7	0	0.0	0.0	**45**	**1.8**
Unstated	0	0.0	0.0	3	100.0	0.1	0	0.0	0.0	**3**	**0.1**
Total	**128**	**5.1**		**2366**	**94.7**		**4**	**0.2**		2498	

*of patients who take lipid modifying therapy



X-axis: All sites (Descending order)

Evolocumab* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	2	0.4	18.2	451	99.3	18.5	1	0.2	25.0	**454**	**18.2**
T2DM	8	0.4	72.7	1931	99.4	79.4	3	0.2	75.0	**1942**	**77.6**
Don't know	1	20.0	9.1	4	80.0	0.2	0	0.0	0.0	**5**	**0.2**
Other	0	0.0	0.0	44	100.0	1.8	0	0.0	0.0	**44**	**1.8**
Unstated	0	0.0	0.0	3	100.0	0.1	0	0.0	0.0	**3**	**0.1**
Total	**11**	**0.4**		**2433**	**99.4**		**4**	**0.2**		2448	

*of patients who take lipid modifying therapy



X-axis: All sites (Descending order)

Other lipid modifying therapy* use by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	5	1.1	13.9	444	98.2	18.5	0	0.0	NA	**452**	**18.1**
T2DM	29	1.5	80.6	1901	98.2	79.4	0	0.0	NA	**1936**	**77.4**
Don't know	1	25.0	2.8	3	75.0	0.1	0	0.0	NA	**4**	**0.2**
Other	1	2.3	2.8	43	97.7	1.8	0	0.0	NA	**44**	**1.8**
Unstated	0	0.0	0.0	3	100.0	0.1	0	0.0	NA	**3**	**0.1**
Total	**36**	**1.5**		**2394**	**98.2**		**0**	**0.0**		2439	

*of patients who take lipid modifying therapy













X-axis: All sites (Descending order)

Aspirin use by diabetes type

Diabetes type	Yes			No			Contraindicated			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	180	14.2	16.2	1087	85.7	34.5	1	0.1	NA	**1268**	**29.7**
T2DM	901	31.3	81.3	1963	68.3	62.2	11	0.4	NA	**2875**	**67.3**
Don't know	4	33.3	0.4	8	66.7	0.3	0	0.0	NA	**12**	**0.3**
Other	20	19.6	1.8	82	80.4	2.6	0	0.0	NA	**102**	**2.4**
Unstated	3	17.6	0.3	14	82.4	0.4	0	0.0	NA	**17**	**0.4**
Total	**1108**	**25.9**		**3154**	**73.8**		**0**	**0.0**		4274	



















X-axis: All sites (Descending order)

Other antiplatelet therapy by diabetes type

Diabetes type	Yes			No			Contraindicated (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	44	3.5	16.2	1223	96.5	30.7	0	0.0	NA	**1267**	**29.7**
T2DM	223	7.8	82.3	2641	92.1	66.2	4	0.1	NA	**2868**	**67.3**
Don't know	0	0.0	0.0	10	100.0	0.3	0	0.0	NA	**10**	**0.2**
Other	3	2.9	1.1	99	97.1	2.5	0	0.0	NA	**102**	**2.4**
Unstated	1	5.9	0.4	16	94.1	0.4	0	0.0	NA	**17**	**0.4**
Total	**271**	**6.4**		**3989**	**93.6**		**0**	**0.0**		4264	





X-axis: All sites (Descending order)

Number of glucose lowering drugs by diabetes type

Diabetes type	0 (Not graphed)			1			2			3			≥4 (Not graphed)		
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%
T1DM	0	0.0	0.0	1240	88.1	66.3	143	10.2	13.4	20	1.4	2.0	4	0.3	1.0
T2DM	150	5.1	64.1	536	18.3	28.7	871	29.7	81.8	981	33.4	96.5	397	13.5	97.3
Don't know	69	50.7	29.5	45	33.1	2.4	15	11.0	1.4	5	3.7	0.5	2	1.5	0.5
Other	15	12.9	6.4	49	42.2	2.6	36	31.0	3.4	11	9.5	1.1	5	4.3	1.2
Unstated	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Total	**234**	**5.1**		**1870**	**40.7**		**1065**	**23.2**		**1017**	**22.1**		**408**	**8.9**	

Diabetes Type	Total	
	n	%
T1DM	1407	30.6
T2DM	2935	63.9
Don't know	136	3.0
Other	116	2.5
Unstated	NA	NA
Total	4594	















X-axis: All sites (Descending order)

Number of anti-hypertensive drugs by diabetes type

Diabetes type	1			2			3			≥4 (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	274	19.5	20.4	110	7.8	14.2	43	3.1	13.0	6	6.4	6.4	**1407**	**30.3**
T2DM	1030	35.1	76.6	652	22.2	83.9	279	9.5	84.3	86	2.9	91.5	**2935**	**63.2**
Don't know	6	4.4	0.4	1	0.7	0.1	2	1.5	0.6	1	0.7	1.1	**136**	**2.9**
Other	30	25.9	2.2	11	9.5	1.4	7	6.0	2.1	1	0.9	1.1	**116**	**2.5**
Unstated	5	10.6	0.4	3	6.4	0.4	0	0.0	0.0	0	0.0	0.0	**47**	**1.0**
Total	**1345**	**29.0**		**777**	**16.7**		**331**	**7.1**		**94**	**2.0**		4641	

* of patients who take anti-hypertensive therapy



















X-axis: All sites (Descending order)

Liver disease by diabetes type

Diabetes type	Mild			Moderate			Nil (Not graphed)			Total	
	n	R%	C%	n	R%	C%	n	R%	C%	n	%
T1DM	64	5.2	15.3	21	1.7	11.6	1152	93.1	32.4	**1237**	**29.8**
T2DM	343	12.3	82.1	150	5.4	82.9	2300	82.3	64.7	**2793**	**67.2**
Don't know	0	0.0	0.0	0	0.0	0.0	11	100.0	0.3	**11**	**0.3**
Other	9	9.2	2.2	10	10.2	5.5	79	80.6	2.2	**98**	**2.4**
Unstated	2	12.5	0.5	0	0.0	0.0	14	87.5	0.4	**16**	**0.4**
Total	**418**	**10.1**		**181**	**4.4**		**3556**	**85.6**		4155	













X-axis: All sites (Descending order)

Table 7.1 Demographic data

Category	2022	2021	2019
Number of patients, n	**4641**	4484	6116
Age (years), mean ± SD	**57.2 ± 17.7**	57.6 ± 17.3	57.2 ± 17.3
Diabetes duration (years), median (IQR)	**17.1 (9 – 26)**	14.0 (7 - 22)	14.0 (6 - 21)
Female, %	**45.5**	45.5	47.4
Pregnant, % (females aged 18-55 years)	**5.3**	5.7	6.8
Diabetes type, %			
T1DM	**30.6**	29.2	28.4
T2DM	**63.9**	67.7	68.0
Don't know	**3.0**	0.6	1.5
Other	**2.5**	2.5	2.1
Unstated	**1.0**	0.4	0.4
Initial visit, %	**17.8**	14.0	19.7
Interpreter required, %	**2.9**	NA	NA
Aboriginal/Torres Strait Islander, %	**7.6**	3.5	4.2
DVA patient, %	**1.8**	1.3	1.2
NDSS member, %	**88.5**	94.0	94.8

Table 7.2 Overall mean data

Metabolic data	2022 Mean + SD	2021 Mean + SD	2019 Mean + SD
HbA_{1c} (%)	**8.4 ± 1.9**	8.3 ± 1.7	8.1 ± 1.8
HbA_{1c} (mmol/mol)	**67.8 ± 20.7**	66.8 ± 19.2	65.4 ± 19.8
Systolic BP (mmHg)	**132 ± 17**	132 ± 17	132 ± 17
Diastolic BP (mmHg)	**77 ± 11**	76 ± 11	76 ± 11
Total cholesterol (mmol/L)*	**4.3 ± 1.5**	4.3 ± 1.2	4.3 ± 1.2
HDL cholesterol (mmol/L)*	**1.2 ± 0.4**	1.2 ± 0.4	1.2 ± 0.4
LDL cholesterol (mmol/L)*	**2.2 ± 1.0**	2.2 ± 1.0	2.2 ± 0.9
Non-HDL cholesterol (mmol/L)*	**3.1 ± 1.5**	3.1 ± 1.2	3.1 ± 1.1
Triglyceride (mmol/L)*, median (IQR)†	**1.6 (1.1 - 2.4)**	1.6 (1.1 - 2.4)	1.6 (1.1 - 2.3)
BMI (kg/m²)	**31.3 ± 7.7**	31.5 ± 7.7	31.7 ± 9.5

*Irrespective of fasting status
†Reported as median (IQR) as data were not normally distributed

Table 7.3. Risk factors for cardiovascular disease

Risk factors	2022 %	2021 %	2019 %
Current smoker	**15.1**	11.4	12.3
Past smoker	**31.0**	31.9	31.7
On anti-hypertensive therapy	**59.9**	60.4	60.6
On lipid modifying therapy	**60.0**	61.5	58.7
Blood pressure ≥130/80 mmHg	**68.2**	54.2	54.2
Blood pressure ≥140/90 mmHg	**36.2**	28.4	28.4
Raised total cholesterol ≥4.0 mmol/L	**56.3**	56.2	58.0
Raised LDL cholesterol ≥2.0 mmol/L	**54.8**	53.0	55.2
Reduced HDL cholesterol <1.0 mmol/L	**28.2**	27.8	25.1
Raised triglycerides ≥2.0 mmol/L	**37.2**	38.1	35.5
Raised non-HDL cholesterol ≥2.5 mmol/L	**66.4**	40.0	41.9
Overweight/obese ≥25 kg/m²	**79.5**	80.7	81.6

Table 7.4 Treatment of cardiovascular risk factors

Treatment	2022 %	2021 %	2019 %
On anti-hypertensive therapy	**59.9**	60.4	60.6
On lipid modifying therapy	**60.0**	61.5	58.7
On anti-platelet therapy	**28.9**	30.5	30.5

Table 7.5. Glycaemic emergencies in the last 12 months in patients with T1DM

Complications/event	2022 %	2021 %	2019 %
Diabetic ketoacidosis	**7.8**	7.3	8.3
Hyperosmolar hyperglycaemic state	**0.2**	0.2	0.7
Severe hypoglycaemia	**9.3**	4.5	5.9
1-2 episodes	**5.7**	5.4	9.6
3-5 episodes	**1.7**	1.5	2.3
>5 episodes	**1.3**	1.2	2.2
Unstated	**0.6**	0.7	0.2

Table 7.6. Glycaemic emergencies in the last 12 months in patients with T2DM

Complications/event	2022 %	2021 %	2019 %
Diabetic ketoacidosis	**1.1**	0.9	1.0
Hyperosmolar hyperglycaemic state	**1.1**	1.0	1.2
Severe hypoglycaemia	**1.8**	4.5	5.9
1-2 episodes	**1.0**	1.5	1.9
3-5 episodes	**0.5**	0.5	0.5
>5 episodes	**0.3**	0.3	0.1
Unstated	**0.0**	0.1	0.0

Table 7.7. Eye complications in the last 12 months

Eye testing and complications	2022 %	2021 %	2019 %
Attended optometrist/ophthalmologist	**75.3**	77.3	78.1
Retinopathy	**16.0**	19.7	18.1
Treatment for retinopathy	**6.4**	8.8	8.7
Cataract	**11.7**	18.5	17.5
Blindness	**2.0**	1.9	1.4

Table 7.8. Eye complications prior to the last 12 months

Eye testing and complications	2022 %	2021* %	2019* %
Retinopathy	**18.4**	NA	NA
Treatment for retinopathy	**11.4**	NA	NA
Cataract	**16.4**	NA	NA
Blindness	**1.8**	1.6	1.7

*Historical data on eye testing, retinopathy (including treatment), and cataract were not collected

Table 7.9. Foot complications in the last 12 months

Foot complications	2022 %	2021 %	2019 %
Foot ulceration	**5.3**	5.8	5.2
Peripheral neuropathy	**21.0**	22.3	19.9
Lower limb amputation*	**1.8**	1.7	2.8
Minor	**1.2**	1.5	2.3
Major	**0.5**	0.2	0.5

*Missing data for a small number of patients

Table 7.10. Foot complications prior to the last 12 months

Foot complications	2022 %	2021 %	2019 %
Foot ulceration	**6.4**	7.2	5.7
Peripheral neuropathy	**17.7**	22.3	18.3
Lower limb amputation*	**2.6**	2.5	3.3
Minor	**1.8**	1.9	2.5
Major	**0.7**	0.5	0.8

*Missing data for a small number of patients

Table 7.11. Kidney complications

Kidney complications	2022 %	2021 %	2019 %
Albuminuria*			
Normal to mildly increased albuminuria	**58.4**	61.8	58.4
Moderately increased albuminuria	**29.7**	28.1	29.7
Severely increased albuminuria	**12.0**	10.0	12.0
Chronic Kidney Disease*			
Stage 1	**14.0**	10.6	10.7
Stage 2	**10.6**	12.3	12.6
Stage 3	**28.9**	26.9	20.9
Stage 4	**5.5**	5.0	4.0
Stage 5	**2.3**	2.6	2.2
End stage renal disease	**4.3**	4.2	4.1

*Refer to Annual Report for thresholds

Table 7.12. Cardiovascular complications in the last 12 months

Complication/event	2022 %	2021 %	2019 %
Myocardial infarction	**2.7**	2.9	2.5
CABG/angioplasty	**2.8**	2.7	2.4
Cerebral stroke	**1.5**	1.3	1.5
Congestive cardiac failure	**4.2**	4.4	4.5
Peripheral vascular disease	**8.5**	7.6	7.7

Table 7.13. Cardiovascular complications prior to the last 12 months

Complication/event	2022 %	2021 %	2019 %
Myocardial infarction	**9.9**	10.2	9.6
CABG/angioplasty	**10.2**	10.0	9.9
Cerebral stroke	**5.4**	5.1	4.4
Congestive cardiac failure	**4.5**	4.9	5.3
Peripheral vascular disease	**7.4**	10.0	8.5

Table 7.14. Other complications and comorbidities in the last 12 months

Complication/event	2022 %	2021 %	2019 %
Depression	**20.0**	NA	NA
Sexual dysfunction	**12.1**	12.2	12.1
Malignancy	**3.6**	NA	NA
Dementia	**3.0**	1.4	1.4
COVID-19	**20.3**	NA	NA
Hospitalisation for COVID-19*	**8.4**	NA	NA
Liver disease			
Mild	**10.1**	9.0	7.6
Moderate/Severe	**4.3**	2.7	2.8

*Of those patients who reported COVID-19

Table 7.15. Other complications and comorbidities prior to the last 12 months

Complication/event	2022 %	2021 %	2019 %
Depression	**19.6**	NA	NA
Sexual dysfunction	**11.6**	11.2	11.6
Malignancy	**7.3**	NA	NA
Dementia	**2.1**	0.8	1.1
COVID-19	**1.5**	NA	NA
Hospitalisation for COVID-19*	**8.1**	NA	NA

*Of those patients who reported COVID-19. Historical data on liver disease was not collected.

Table 7.16 Blood glucose control, age, BMI and diabetes duration by diabetes type

Category	2022 Mean ± SD	2021 Mean ± SD	2019 Mean ± SD
HbA_{1c} (%)			
T1DM	**8.4 ± 1.8**	8.4 ± 1.7	8.4 ± 1.7
T2DM	**8.3 ± 1.9**	8.2 ± 1.8	8.1 ± 1.8
T2DM diet only	**6.7 ± 1.3**	6.8 ± 1.4	6.5 ± 1.3
T2DM tablets only	**8.4 ± 1.9**	8.2 ± 1.7	8.1 ± 1.8
T2DM insulin only	**8.7 ± 1.9**	8.6 ± 1.7	8.5 ± 1.9
T2DM insulin & tablets	**8.8 ± 1.9**	8.6 ± 1.7	8.6 ± 1.8
Age (years)			
T1DM	**44.2 ± 17.9**	43.6 ± 17.4	43.0 ± 16.9
T2DM	**63.8 ± 13.5**	63.7 ± 13.3	63.5 ± 13.3
T2DM diet only	**68.6 ± 14.7**	65.7 ± 14.7	65.7 ± 15.9
T2DM tablets only	**63.4 ± 13.3**	63.3 ± 13.1	63.0 ± 12.9
T2DM insulin only	**64.5 ± 13.1**	64.2 ± 12.6	64.1 ± 12.8
T2DM insulin & tablets	**64.3 ± 12.9**	63.9 ± 12.4	63.7 ± 12.4
BMI (kg/m^2)			
T1DM	**27.9 ± 6.0**	26.6 ± 5.3	26.6 ± 5.3
T2DM	**33.2 ± 7.9**	32.6 ± 7.2	32.6 ± 7.2
T2DM diet only	**31.2 ± 6.8**	32.4 ± 7.1	31.3 ± 6.4
T2DM tablets only	**33.2 ± 7.8**	33.5 ± 7.9	33.6 ± 8.3
T2DM insulin only	**33.4 ± 7.9**	33.8 ± 8.0	33.7 ± 7.9
T2DM insulin & tablets	**33.3 ± 7.6**	34.2 ± 8.0	34.1 ± 8.0
Duration of diabetes (years)	Median (IQR)	Median (IQR)	Median (IQR)
T1DM	**17.4 (7.4 – 30.5)**	18.0 (10.0 – 30.0)	18.0 (10.0 – 29.0)
T2DM	**12.4 (5.3 – 20.5)**	13.0 (6.0 – 21.0)	12.0 (6.0 – 20.0)
T2DM diet only	**2.4 (0.5 – 6.5)**	4.0 (1.0 – 10.0)	5.0 (1.0 – 10.0)
T2DM tablets only	**7.5 (2.0 – 14.1)**	9.0 (3.0 – 16.0)	8.0 (3.0 – 14.0)
T2DM insulin only	**17.4 (8.5 – 23.4)**	20.0 (11.0 – 26.0)	17.0 (10.0 – 24.0)
T2DM insulin & tablets	**17.5 (10.4 – 24.4)**	17.0 (10.0 – 23.0)	16.0 (10.0 – 22.0)

Participating sites were asked to complete a questionnaire at the completion of the data collection phase, to assess the participating sites' satisfaction with the overall process of data collection. Free text responses to questions were reviewed individually and utilised to refine the data collection instrument and reporting process for future audits.

Table 7.17 shows the results of the feedback (the Likert Scale responses) from participating sites to the specific questions related to the data collection. The results in 2022 were slightly lower than 2021, but comparable to other previous years. The time needed to complete the data collection form remains of concern to participating sites.

Table 7.17 Post Data Collection Questionnaire Results

Questionnaire category	Likert Scale: 1 = Poor, 3 = Midpoint, 5 = Good (Mean + SD)				
	2022 (n=31)	2021 (n=25)	2019 (n=68)	2017 (n=43)	2015 (n=37)
Information package/letters	**4.4 ± 0.6**	4.6 ± 0.6	4.4 ± 0.7	4.1 ± 0.7	4.3 ± 0.7
Data definitions form	**4.2 ± 0.6**	4.6 ± 0.6	4.3 ± 0.7	4.0 ± 0.8	4.0 ± 0.7
Format (layout of data items)	**3.7 ± 0.9**	4.2 ± 0.7	4.0 ± 1.0	3.7 ± 1.0	3.8 ± 0.9
Ease of form completion	**3.6 ± 1.0**	4.1 ± 0.7	3.7 ± 1.0	3.4 ± 1.2	3.7 ± 1.1
Time to complete the form	**2.8 ± 1.2**	3.7 ± 1.1	3.1 ± 1.1	2.6 ± 1.7	3.1 ± 1.0

The results in Table 7.18, from 31 respondents, showed that there was general approval of the 'Process' including the information provided, data definitions form and overall format. The results were slightly lower compared to 2021 for both paper-based and web-based data collections.

Table 7.18 Post Data Collection Questionnaire – Response by data collection method

Questionnaire category	Likert Scale 1= Poor, 3= Midpoint, 5= Good (Mean ± SD)						
	Paper-based			Web-based		Data Extract	
	2022 (n=22)	2021 (n=14)	2019 (n=46)	2022 (n=7)	2021 (n=10)	2019 (n=20)	2022 (n=2)
Information package/letters	**4.5 ± 0.6**	4.7 ± 0.5	4.5 ± 0.7	**4.1 ± 0.7**	4.5 ± 0.7	4.2 ± 0.7	**5.0 ± 0.0**
Data Definitions form	**4.2 ± 0.7**	4.7 ± 0.5	4.5 ± 0.7	**4.3 ± 0.5**	4.4 ± 0.7	4.1 ± 0.7	**4.5 ± 0.7**
Format (layout of data items)	**3.5 ± 0.9**	4.1 ± 0.8	4.1 ± 0.8	**4.3 ± 0.8**	4.1 ± 0.6	4.0 ± 0.9	**4.0 ± 0.0**
Ease of completion	**3.5 ± 1.1**	3.9 ± 0.7	3.6 ± 0.9	**4.0 ± 1.0**	4.3 ± 0.7	3.9 ± 0.9	**3.5 ± 0.7**
Time to complete the form	**2.8 ± 1.1**	3.9 ± 0.9	3.1 ± 1.1	**2.9 ± 1.6**	3.5 ± 1.3	3.2 ± 1.0	**3.0 ± 0.0**

Diabetes Publications & Resource List 2020

There are many resources available nationally that provide evidence-based guidelines on how care should be provided and what outcomes should be achieved for people living with diabetes.

The following is a list of commonly used resources in Australia. The list also includes health care organisations involved in the provision of diabetes care. These links have been divided into topics. Please click on the topic of interest.

Contents

Title	Description / Link
Prevention, Prediabetes & Diagnostics	
National Evidence Based Guideline for Case Detection and Diagnosis of Type 2 Diabetes	https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guideline-for-Case-Detection-and-Diagnosis-of-Type-2-Diabetes.pdf
National Evidence Based Guideline for the Primary Prevention of Type 2 Diabetes	https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guidelines-for-the-Primary-Prevention-of-Type-2-Diabetes.pdf
The Australian Diabetes Educators Association (ADEA) and the Australian Diabetes Society (ADS) Position Statement on Prediabetes	https://nadc.net.au/wp-content/uploads/2019/08/The-Australian-Diabetes-Educators-Association-ADEA-and-the-Australian-Diabetes-Society-ADS-Position-Statement-on-pre-diabetes.pdf
Australian Diabetes Society Position Statement: **The Prevention and Management of Type 2 Diabetes in the Context of Psychotic Disorders**	https://diabetessociety.com.au/documents/ADS_Mental_Health_and_T2D_Position_Statement2017.pdf
Life! Program	The Life! program is a free Victorian lifestyle modification program aimed at type 2 diabetes and cardiovascular disease risk reduction. Run by expert health professionals, the program is delivered as a group course or a telephone health coaching service. https://www.lifeprogram.org.au/
Hospital Guidelines	
ADS Guidelines for Routine Glucose Control in Hospital	http://diabetessociety.com.au/documents/ADSGuidelinesforRoutineGlucoseControlinHospitalFinal2012.pdf
ADS Peri-Operative Diabetes Management Guidelines	These guidelines are primarily intended to provide assistance for those practitioners whose primary focus is not diabetes or who do not have the support of local diabetes expertise in their management of patients with diabetes undergoing surgical procedures. http://diabetessociety.com.au/documents/PerioperativeDiabetesManagementGuidelinesFINALCleanJuly2012.pdf
Obesity Management	
Australian Obesity Management Algorithm	This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand. The aims of the document are to: 1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity 2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia. https://diabetessociety.com.au/documents/ObesityManagementAlgorithm18.10.2016FINAL.pdf

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations	The ADS has recently endorsed international guidelines that recommend metabolic surgery for patients with type 2 diabetes and class III (BMI ≥40 kg/m2) obesity and patients with type 2 diabetes with class II (BMI 35.0–39.9 kg/m2) obesity who have had inadequate glycaemic control with lifestyle and pharmacotherapy. https://diabetessociety.com.au/documents/RubinoetalDiabetesCare2016.pdf
Type 1 Diabetes	
Alcohol and type 1 diabetes	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/a956cdaa-b77c-466e-9772-f265ec83183f.pdf
Diabetes in Pregnancy booklet for women with type 1 – Having a Healthy Baby	https://nadc.net.au/wp-content/uploads/2019/08/Diabetes-in-Pregnancy-booklet-for-women-with-type-1-%E2%80%93-Having-a-Healthy-Baby.pdf
Drug use and type 1 diabetes	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/00c929cf-b50b-4ef4-8792-8d12ac488af2.pdf
Guidelines for Sick Day Management for People with Diabetes	Provides readily accessible information recommending strategies for managing sick days in diabetes. To view the technical document for health professional: https://nadc.net.au/wp-content/uploads/2019/08/Guidelines-for-Sick-Day-Management-for-People-with-Type-1-and-2-Diabetes.pdf To view the sick day management of adults with type 1 diabetes consumer resources: https://nadc.net.au/wp-content/uploads/2019/08/Guidelines-for-Sick-Day-Management-for-People-with-Type-1.pdf
NDSS Pregnancy and Diabetes Website	Information for women with type 1 or type diabetes planning a pregnancy now or in the future https://www.ndss.com.au/about-diabetes/pregnancy/
National Evidence Based Clinical Care Guidelines for Type 1 Diabetes in Children, Adolescents and Adults	http://diabetessociety.com.au/downloads/Type1guidelines14Nov2011_000.pdf
Travelling and type 1 diabetes	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/2e44a739-242e-4a2e-97d0-3874359b907c.pdf
Understanding Hypoglycaemia	The International Hypoglycaemia Study Group (IHSG) has launched a website providing information about hypoglycaemia in diabetes. It includes statements and guidelines, practice tools for health professionals and much more. https://ihsgonline.com/
Type 2 Diabetes	
ADS Position Statement on A New Blood Glucose Management Algorithm for Type 2 Diabetes	This position statement developed by the Australian Diabetes Society outlines the risks, benefits and costs of the available therapies and suggests a treatment algorithm incorporating the older and newer agents. Summary of this ADS Position Statement is as follows: To read or download the full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement (Updated: December, 2016)

	https://diabetessociety.com.au/documents/ADS_POSITIONSTATEMENT_v2.4.pdf
T2D Treatment Website (A New Blood Glucose Management Algorithm for Type 2 Diabetes)	The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents. To view the algorithm and associated resources: http://t2d.diabetessociety.com.au/
Diabetes Management in General Practice 2016/18	General practitioners continue to provide most of the medical support to people with type 2 diabetes. This guide plays an important role in providing a readable summary of current guidelines and recommendations from various sources on the management of type 2 diabetes in the general practice setting. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf
Australian Diabetes Society Position Statement: **The Prevention and Management of Type 2 Diabetes in the Context of Psychotic Disorders**	To read or download your copy, please click here https://nadc.net.au/wp-content/uploads/2019/08/Australian-Diabetes-Society-Position-Statement-The-Prevention-and-Management-of-Type-2-Diabetes-in-the-Context-of-Psychotic-Disorders-1.pdf
National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes	http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/14d82dbb-d776-40c5-a848-9b22f251514e.pdf
Elderly / Aged Care / End of Life	
Glucose Lowering Medicines and Older People with Diabetes: Information for Personal Care Workers	This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site. https://nadc.net.au/wp-content/uploads/2019/08/GLM-PCW.pdf
Glucose Lowering Medicines and Older People with Diabetes: Information for Registered and Enrolled Nurses	This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site. https://nadc.net.au/wp-content/uploads/2019/08/GLM-Nurses.pdf
Glucose Lowering Medicines: Information for Older People with Diabetes and their Family Members	This is the links to the Q-Med project resources which are available on the Australian Disease Management Association (ADMA) Online Clearinghouse site. https://nadc.net.au/wp-content/uploads/2019/08/GLM-PWD.pdf
Aged Care Diabetes Care Checklist	This is a checklist to assist in the management of diabetes care for the aged. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/81e7639f-0d20-4461-b0c8-c3be51cbe7ce.pdf
Diabetes Management in Aged Care: A practical handbook	This is an updated version of the resource developed in 2012 and is aimed at care staff. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/ae2124a0-5695-4adf-ba27-f5408b19089d.pdf
Diabetes Management in Aged Care: Fact sheets for care workers	The diabetes management in aged care fast facts for care workers is a booklet of quick reference sheets that aim to give care staff basic

	information on how to manage diabetes in a residential care setting: To read or download your copy of the E-book: https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/f49f1343-e606-4dad-ac63-16bcced3a313.pdf
Guidelines for Managing Diabetes at the End of Life	These guidelines were developed in 2014 to assist with the management of Diabetes at the End of Life. To access these guidelines, search for these on the ADMA website. https://adma.org.au/
Older People – Healthy Eating Guide	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/1581db13-3932-40fe-a46b-fcd719c60bdf.pdf
Older People – Managing Diabetes as You Age	https://www.ndss.com.au/wp-content/uploads/resources/booklet-managing-diabetes-as-you-age-guide-for-people-over-65.pdf
Older People – You and your Health Care Team	https://www.ndss.com.au/wp-content/uploads/resources/booklet-your-health-care-team-guide-for-people-over-65.pdf
The McKellar guidelines for Managing Older people with Diabetes in Residential and Other Care Settings	These Guidelines were developed in 2014 to assist with the management of Diabetes in Residential Care Facilities. To access these guidelines, search for these on the ADMA website. https://nadc.net.au/wp-content/uploads/2019/08/The-McKellar-Guidelines-for-Managing-Older-People-with-Diabetes-in-Residential-and-Other-Care-Settings_v3_e.pdf
Consulting / Diabetes Education	
A new language for diabetes – Improving communications with and about people with diabetes	Diabetes Australia has released an updated version (May 2016) of their position statement on language around diabetes. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/f4346fcb-511d-4500-9cd1-8a13068d5260.pdf
The use of Language in Diabetes Care and Education	Article from The American Association of Diabetes Educators (AADE) and American Diabetes Association on the use of language in Diabetes Care and Education. https://nadc.net.au/wp-content/uploads/2019/08/The-use-of-Language-in-Diabetes-Care-and-Education.pdf
Enhancing your consulting skills	"Enhancing Your Consulting Skills" was developed by the ADS for the NDSS. It is now available in electronic format through the ADS website. It can be downloaded free of charge for individual use. Please note that you will be required to submit a request for download and obtain your password prior to receiving the download link. Hard copies of the resource are available from the ADS Secretariat. http://diabetessociety.com.au/download-request.asp
National Evidenced Based Guideline for Patient Education in Type 2 Diabetes	This document provides minimum standards for development and facilitation of diabetes education programs. http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/b9b8789d-c7ba-473d-bd49-0b7d793a0835.pdf
Outcomes and Indicators for Diabetes Education: National Consensus Position Information and	This report details a systematically derived framework of nationally agreed goals, outcomes and indicators for diabetes education. It

Education for People with Diabetes: a 'Best Practice' Strategy	provides a benchmark and policy platform for refining and evaluating the consistency, quality and effectiveness of diabetes education services which can be applied nationally and/or at a regional or local service level. https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/281a322b-44df-43f8-b407-39dca2136011.pdf
Renal Information	
National Evidence Based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes	http://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/14d82dbb-d776-40c5-a848-9b22f251514e.pdf
Foot Care	
• Australasian Podiatry Council • Limbs 4 Life • Diabetic Foot Australia	
National Evidence Based Guidelines on Prevention, Identification and Management of Foot Complications in Diabetes	Approved by the NHMRC, the full guideline, clinical guide, consumer guides and technical report can be downloaded: https://nadc.net.au/wp-content/uploads/2019/08/National-Evidence-Based-Guidelines-on-Prevention-Identification-and-Management-of-Foot-Complications-in-Diabetes.pdf
Standards for High Risk Foot Services (HRFS) in NSW	To view or download your copy, please **TBA**
Promoting Optimal Diabetes Foot Care	"Promoting Optimal Diabetes Foot Care" is a set of audio-visual resources based on national and international guidelines. The resources have been designed to help health professionals develop the clinical skills required to deliver high quality foot care to people with diabetes. The set is comprised of three learning modules: 1. The Foot Examination https://diabetessociety.com.au/diabetesfoot/the-foot-examination-submit-request.asp 2. Preventative Foot Care https://diabetessociety.com.au/diabetesfoot/preventative-foot-care-submit-request.asp 3. Managing basic diabetes foot complications https://diabetessociety.com.au/diabetesfoot/managing-foot-complications-submit-request.asp
Wound Institute of Australia	The Wound Healing Institute of Australia has developed a comprehensive set of modules on wound care, including specific modules on foot ulcers and leg ulcers. Find out more about these modules at: https://www.whia.com.au/product-category/online-learning/
NADC Foot Network	2017 ASM Presentation by Stephen Twigg and Leanne Mullan – Slides can be viewed (part 1) and (part 2)

	https://nadc.net.au/wp-content/uploads/2020/01/ASM-Meet-the-expert-Twigg-Mullan-2017-Part-1.pdf https://nadc.net.au/wp-content/uploads/2020/01/ASM-Meet-the-expert-Twigg-Mullan-2017-Part-2.pdf
Eye Care	
• Optometrists Association of Australia	
Diabetes Educators	
National Core Competencies for Credentialled Diabetes Educators	Provides a reference and a framework for guiding policy on the training and credentialing of diabetes educators. https://nadc.net.au/wp-content/uploads/2019/08/National-Core-Competencies-for-Credentialled-Diabetes-Educators.pdf
National Standards of Practice for Diabetes Educators	One of the strategies developed by ADEA to promote a quality professional diabetes education practice. https://nadc.net.au/wp-content/uploads/2019/08/National-Standards-of-Practice-for-Diabetes-Educators.pdf
The Role of Credentialled Diabetes Educators and Accredited Practising Dietitians in the Delivery of Diabetes Self-Management and Nutrition Services for People with Diabetes	https://nadc.net.au/wp-content/uploads/2019/08/The-Credentialled-Diabetes-Educator-in-Australia-%E2%80%93-Role-and-Scope-of-Practice.pdf
Fact Sheets / Patient Resources	
Baker IDI Fact Sheets	These materials have been developed by Baker IDI experts for use by clients and health professionals for patient education. The Institute is committed to providing credible, evidence-based health information regarding optimum approaches to the prevention and management of disease. https://www.bakeridi.edu.au/health-hub/fact-sheets
Diabetes Australia patient information and resources	https://www.diabetesaustralia.com.au/
National Diabetes Services Scheme (NDSS) resources including fact sheets	35 facts sheets including those in other languages are available through the NDSS website. https://www.ndss.com.au/about-diabetes/resources/
Diabetes and Emotional Health Handbook and Toolkit	'Diabetes and Emotional Health' is a handbook and toolkit developed as part of the National Diabetes Services Scheme Mental Health and Diabetes National Development Programme. The handbook has been designed as an evidence-based, practical resource to enable health professionals to identify, address, and communicate about emotional problems during consultations with adults with diabetes. A related toolkit contains resources to complement the handbook, including summary cards of several chapters, questionnaires for routine clinical use, and related 'factsheets' for people with diabetes. The latter provide information about the psychological topics covered in the chapters of the handbook, tips about what people with diabetes can do when they experience this problem and where they can get further support. Both the handbook and the toolkit can be accessed electronically via the Health Professionals tab of the NDSS website

	(ndss.com.au). The direct link is www.ndss.com.au/online-resources-for-health-professionals (you will need to 'sign up' to view it). The 'factsheets' are also available directly to people with diabetes electronically via the NDSS website. The direct link is https://www.ndss.com.au/diabetes-and-emotional-health.
Nutrition / Diet	
• Dietitians Association of Australia (DAA) • Food Standards Australia New Zealand (FSANZ) • Glycemic Index Ltd • Nutrition Australia • Coeliac Australia • Diabetes Australia recipes	
Healthy Eating Guide for Older Australians with Diabetes	https://www.ndss.com.au/wp-content/uploads/resources/booklet-healthy-eating-guide-for-people-over-65.pdf
Diabetes and Ramadan	To assist health professionals, religious leaders and people with diabetes who fast during Ramadan, the Australian Diabetes Society, in conjunction with the International Diabetes Federation and Diabetes and Ramadan International Alliance, has endorsed the following brochures: • Diabetes during Ramadan: Patient Guide https://nadc.net.au/wp-content/uploads/2019/08/Diabetes-during-Ramadan-Patient-Guide.pdf • Ramadan and Diabetes: Guidance Sheet for Imam https://nadc.net.au/wp-content/uploads/2019/08/Ramadan-and-Diabetes-Guidance-Sheet-for-Imam.pdf • Management of Diabetes During Ramadan: Quick Reference Guide for Health Professionals https://nadc.net.au/wp-content/uploads/2019/08/Management-of-Diabetes-During-Ramadan-Quick-Reference-Guide-for-Health-Professionals.pdf In February 2017 the NADC joined representatives from the ADS and the Diabetes and Ramadan (DaR) International Alliance at the first-ever Diabetes and Ramadan Symposium at Concord Repatriation General Hospital. The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which aim to support healthcare professionals to better support patients during this important religious period. A copy of the guidelines can be downloaded from the IDF website at http://www.idf.org/guidelines/diabetes-in-ramadan and presentations from the event can be viewed here: http://nadc.net.au/video/ or via the NADC YouTube channel - NADC Australia. Diabetes and Ramadan Overview • https://www.youtube.com/watch?v=9Cil643q8UQ&t=43s Diabetes and Ramadan Symposium Introduction - Dr Sof Andrikopoulos

	• https://www.youtube.com/watch?v=ZuSSCI3OIGU Diabetes and Ramadan Dr Marwan Obaid • https://www.youtube.com/watch?v=3lX6hd2sy6w&t=179s Diabetes and Ramadan 2 Case Studies Dr Elif Ekinci • https://www.youtube.com/watch?v=VTPkSqum3cA&t=19s Ramadan, Diabetes and Pregnancy Dr Sarah Abdo • https://www.youtube.com/watch?v=GjCUBkErI6g IDF DAR Practical Guidelines Dr Mohamed Hassanein • https://www.youtube.com/watch?v=2NUF0sVrYaw&t=83s
Pregnancy • The Australasian Diabetes in Pregnancy Society (ADIPS) https://www.adips.org/Index.asp • Pregnancy and Diabetes http://pregnancyanddiabetes.com.au/	
Diabetes in Pregnancy booklet for women with type 1 – Having a Healthy Baby	https://www.ndss.com.au/wp-content/uploads/resources/booklet-pregnancy-having-healthy-baby-type1.pdf
Diabetes in Pregnancy booklet for women with type 2 – Having a Healthy Baby	http://www.pregnancyanddiabetes.com.au/globalassets/pdfs/pregnancy_having-healthy-baby-t2-booklet_aug15.pdf
Gestational Diabetes - Caring for Yourself and Your Baby	https://www.ndss.com.au/wp-content/uploads/resources/booklet-gestational-diabetes-caring-for-yourself-and-baby.pdf
Life after Gestational Diabetes	https://www.ndss.com.au/wp-content/uploads/resources/booklet-gestational-diabetes-life-after.pdf
NDSS Understanding Gestational Diabetes Factsheet	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/86373a1a-2f2f-4f73-a872-7f9f3a45b1cf.pdf Also available in 10 different languages, to view or download translated factsheets: https://www.ndss.com.au/about-diabetes/information-in-your-language
NDSS Pregnancy Planning Checklist	http://www.pregnancyanddiabetes.com.au/static/assets/staticchecklist.pdf
NDSS Pregnancy and Diabetes Factsheet	To view or download your copy, please click here https://www.ndss.com.au/wp-content/uploads/fact-sheets/fact-sheet-pregnancy-and-diabetes.pdf Also available in 10 different languages, to view or download translated factsheets: https://www.ndss.com.au/about-diabetes/information-in-your-language/

Aboriginal and Torres Strait Islander • HealthInfoNet	
Aboriginal and Torres Strait Islander Resources – NDSS	https://www.ndss.com.au/living-with-diabetes/about-you/aboriginal-and-torres-strait-islander-peoples/resources/
Aboriginal and Torres Strait Islander Resources – Diabetes Australia State Branches	Diabetes Victoria - https://www.diabetesvic.org.au/ATSI-resources Diabetes Queensland - https://www.diabetesqld.org.au/managing-diabetes/aboriginal-and-torres-strait-islander.aspx https://www.diabetesqld.org.au/managing-diabetes/aboriginal-and-torres-strait-islander/diabetes-and-me.aspx Diabetes Western Australia - https://diabeteswa.com.au/manage-your-diabetes/resources/aboriginal-health-resources/ Diabetes Tasmania - https://www.diabetestas.org.au/News-and-Resources/Resources/Aboriginal-and-Torres-Strait-Islander-NDSS-Resources Diabetes NSW and ACT - https://diabetesnsw.com.au/useful-tools/information-sheets/indigenous-information-sheets/ Feltman Training - https://www.youtube.com/watch?v=eRIfsTqD7QM&t=327s https://www.diabetesvic.org.au/ATSI-resources
Online Diabetes Education Training Manual for Aboriginal Health Workers	An online training manual has been developed to increase diabetes knowledge among Aboriginal Health Workers to better support Aboriginal and Torres Strait Islander peoples with diabetes and assist them in self-managing their diabetes. This training is targeted to Aboriginal and Torres Strait Islander Health Practitioners and Aboriginal and Torres Strait Islander Health Workers who have completed a minimum of Certificate IV in Aboriginal and/or Torres Strait Islander Primary Health Care (Community Care) or (Practice). This course is available through the ADEA Learning Management System at: learning.adea.com.au https://learning.adea.com.au/lms/login/index.php
Your guide to Medicare for Indigenous health services	The department of Human Services have updated the newly launched education resource, ***"Your guide to Medicare for Indigenous health services"*** to incorporate the important 1 July 2018 Medicare changes. To find more **Indigenous health education** resources please visit Human Services.

CALD / Multilingual	
● Health Translations by the Victorian Government includes translated health information	
Web portal for information about diabetes for people from culturally and linguistically diverse backgrounds	To view or download your copy, please click here https://www.ndss.com.au/about-diabetes/information-in-your-language/
Diabetes and Ramadan	To assist health professionals, religious leaders and people with diabetes who fast during Ramadan, the Australian Diabetes Society, in conjunction with the International Diabetes Federation and Diabetes and Ramadan International Alliance, has endorsed the following brochures: ● Diabetes during Ramadan: Patient Guidehttps://nadc.net.au/wp-content/uploads/2019/08/Diabetes-during-Ramadan-Patient-Guide.pdf ● Ramadan and Diabetes: Guidance Sheet for Imam https://nadc.net.au/wp-content/uploads/2019/08/Ramadan-and-Diabetes-Guidance-Sheet-for-Imam.pdf ● Management of Diabetes During Ramadan: Quick Reference Guide for Health Professionalshttps://nadc.net.au/wp-content/uploads/2019/08/Management-of-Diabetes-During-Ramadan-Quick-Reference-Guide-for-Health-Professionals.pdf In February 2017 the NADC joined representatives from the ADS and the Diabetes and Ramadan (DaR) International Alliance at the first-ever Diabetes and Ramadan Symposium at Concord Repatriation General Hospital. The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which aim to support healthcare professionals to better support patients during this important religious period. A copy of the guidelines can be downloaded from the IDF website at http://www.idf.org/guidelines/diabetes-in-ramadan and presentations from the event can be viewed here: http://nadc.net.au/video/ or via the NADC YouTube channel - NADC Australia. Diabetes and Ramadan Overview ● https://www.youtube.com/watch?v=9Cil643q8UQ&t=43s Diabetes and Ramadan Symposium Introduction - Dr Sof Andrikopoulos ● https://www.youtube.com/watch?v=ZuSSCI3OIGU Diabetes and Ramadan Dr Marwan Obaid ● https://www.youtube.com/watch?v=3lX6hd2sy6w&t=179s Diabetes and Ramadan 2 Case Studies Dr Elif Ekinci ● https://www.youtube.com/watch?v=VTPkSqum3cA&t=19s Ramadan, Diabetes and Pregnancy Dr Sarah Abdo ● https://www.youtube.com/watch?v=GjCUBkErI6g IDF DAR Practical Guidelines Dr Mohamed Hassanein ● https://www.youtube.com/watch?v=2NUF0sVrYaw&t=83s

Data / Research / Quality Improvement	
• Diabetes Australia Research Program https://www.diabetesaustralia.com.au/diabetes-australia-research-program • Juvenile Diabetes Research Foundation (JDRF) https://jdrf.org.au/ • The Australian Centre for Behavioural Research in Diabetes https://acbrd.org.au/ • The Diabetes Research Foundation Western Australia http://www.diabetesresearchfoundation.asn.au/ • The John Curtin School of Medical Research https://jcsmr.anu.edu.au/ • The NHMRC Centre of Clinical Research Excellence on Clinical Science in Diabetes (Diabetes CCRE) http://research.unimelb.edu.au/work-with-us/funding/nhmrc/cre • Baker IDI https://www.baker.edu.au/ • The Walter and Eliza Hall Institute of Medical Research https://www.wehi.edu.au/	
Australian National Diabetes Audit (ANDA) reports	The primary aim of ANDA is to: ·conduct a survey that will assess a standardised set of predefined clinical (AQCA) and self-management diabetes (AQSMA) indicators including demographic and biological variables, and clinical outcomes; ·enable diabetes services to benchmark their practice processes and clinical outcome data against that of other centres; ·enable diabetes services to compare their practice processes and clinical outcome data over time (where participation in previous collections has occurred); and ·provide pooled national data and data grouped by state and metropolitan/regional/remote location on the clinical status of people with diabetes attending diabetes services. This important quality assurance activity promotes continuous improvement in the standard of service provided by diabetes centres and is the primary quality assurance activity of the NADC. To view this data please click here https://nadc.net.au/anda/
ANDA: Lessons from the 2016 Quality Self-Management Audit	ASM 2017 Presentation Slides by Anthony Pease can be accessed here https://nadc.net.au/wp-content/uploads/2019/08/ANDA-2016-at-ADS-2017-1.pdf
NDSS Diabetes Data Snapshots	NDSS national diabetes data snapshots are updated every three months, and provide key statistics for all types of diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes, and insulin therapy. To view or download these snapshots, please click here
Diabetes Map Australia	The Australian Diabetes Map is the only national map monitoring the prevalence of diabetes in Australia. The data contained in the Australian Diabetes Map is derived from the National Diabetes Services Scheme (NDSS) Registrant database* and the Australian Bureau of Statistics (ABS) and shows people diagnosed with diabetes that are registered on the Scheme. It shows the numbers of people diagnosed with diabetes in all parts of Australia with information on age, gender, type of diabetes, ATSI status

	and socio-economic disadvantage. To view the Australian Diabetes Map, please click here https://map.ndss.com.au/#!/
2015 Miles Youth Report	To view or download your copy, please click here https://www.ndss.com.au/wp-content/uploads/resources/report-miles-youth-2015.pdf
HbA1c	
Individualisation of HbA1c targets for Adults with Diabetes Mellitus.	To view or download the full version of this guideline, please click here https://diabetessociety.com.au/documents/HbA1cImplementationv423122014LongVersion.pdf To view or download the short version, please click here https://diabetessociety.com.au/documents/HbA1cPressReleaseADS-July2015.pdf
Subcutaneous Devices / Techniques	
ADEA Clinical Guiding Principles for Subcutaneous Injection Technique	The ADEA Clinical Guiding Principles for Subcutaneous Injection Technique identifies a number of broad clinical issues including optimal needle length and angle of needle insertion for children/adolescents and adults of varying anatomical size. These clinical recommendations reinforce the importance of documenting the process of teaching and reviewing injection technique. To view or download your copy, please Page 38 https://ade.adea.com.au/wp-content/uploads/2017/09/ADE-September-2017-final2.pdf https://ade.adea.com.au/?s=Subcutaneous+injection+technique%3A+an+update+on+the+Australian+guidelines+and+current+evidence&category_name
Australian New Zealand (ANZ) Forum for Injection Technique & Therapy Expert Recommendations (FITTER)	ANZ FITTER Speaker Presentation Slides: Introduction to FITTER Presentation – Prof Glen Maberly • https://nadc.net.au/wp-content/uploads/2020/01/Introduction-to-FITTER-Presentation-Prof-Glen-Maberly.pdf IT in Adults & AU ITQ Findings – Michelle Robins • https://nadc.net.au/wp-content/uploads/2020/01/IT-in-Adults-AU-ITQ-Findings-Michelle-Robins.pdf IT In Children – Prof Paul Hofman • https://nadc.net.au/wp-content/uploads/2020/01/IT-In-Children-Prof-Paul-Hofman.pdf NZ Perspective & IT Trends – Dr Helen Snell & Dr Brandon Orr-Walker

	• https://nadc.net.au/wp-content/uploads/2020/01/NZ-Perspective-IT-Trends-Dr-Helen-Snell-Dr-Brandon-Orr-Walker.pdf The Role of General Prac in IT Education for Patients – Dr Kean-Seng Lim… • https://nadc.net.au/wp-content/uploads/2020/01/The-Role-of-General-Prac-in-IT-Education-for-Patients-Dr-Kean-Seng-Lim....pdf The Role of Pharmacy in IT Education for Patients – Teresa Di Franco • https://nadc.net.au/wp-content/uploads/2020/01/The-Role-of-Pharmacy-in-IT-Education-for-Patients-Teresa-Di-Franco.pdf
Driving	
ADEA Fitness to Drive	The goal of the roll out of *the Support for Health Professionals in the assessment of a person with diabetes and their fitness to drive program* is to ensure a large percentage of health professionals are exposed to the online program and are aware of their obligations under AustRoad's *Assessing Fitness to Drive for commercial and private drivers; Medical Standards for Licensing and Clinical Management Guidelines*. Templates have been developed to assist general practice in implementing discussions around diabetes and driving during consultations: https://members.adea.com.au/resources-2/fitness_to_drive/
Assessing Fitness to Drive	The National Transport Commission and Austroads have released Assessing Fitness to Drive 2017, a new edition of national medical standards for driver licensing. To view or download a copy, please click here https://austroads.com.au/publications/assessing-fitness-to-drive/ap-g56/foreword
Driving and Diabetes in Australia Booklet	https://www.ndss.com.au/wp-content/uploads/resources/booklet-diabetes-and-driving.pdf
Driving and Recent Severe Hypoglycaemia Flyer	https://diabetessociety.com.au/downloads/Driving%20and%20Diabetes%20Flyer.pdf
ADS Position Statement on Insulin-requiring diabetes and recreation diving	https://diabetessociety.com.au/documents/ADS_Diving_Diabetes_2016_Final.pdf
Workplace	
An Employee's Guide to Diabetes in the Workplace	This booklet was developed in response to questions, concerns and suggestions Diabetes Australia received from members of the diabetes community about diabetes in the workplace. https://www.diabetesqld.org.au/media/42934/daq_employee_guide.pdf

Diabetes Victoria Diabetes in the Workplace	Diabetes Victoria have developed booklets about diabetes in the workplace for people with diabetes, their employees and co-workers. To access these booklets and additional information from Diabetes Victoria: https://www.diabetesvic.org.au/diabetes-and-me-type?tags=Left-Mega-Nav%2Fliving%20with%20diabetes%2FDiabetes%20in%20the%20workplace%2F&bdc=1 • An employer's guide to diabetes in the workplace (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f900000071gHsAAI.pdf • An employee's guide to diabetes in the workplace (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f900000071gHnAAI.pdf • Diabetes in the workplace: explanatory notes for health professionals (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f900000071gHiAAI.pdf • Diabetes in the workplace checklist (PDF) https://s3-ap-southeast-2.amazonaws.com/dv-resources/OrchestraCMS/a1f900000071gHdAAI.pdf
NDSS	
Blood Glucose Test Strip Six Month Approval – NDSS	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/cb3d57f6-dc1a-40d3-b44b-c15a82c038cb.pdf
Medication Change Form – NDSS	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5734f97b-1f62-42a2-a774-ae233a83eee6.pdf
Registration Form - NDSS	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/ce7d2178-f159-45c4-8b2b-1142622b84f4.pdf
Personal Details Update Form - NDSS	https://www.ndss.com.au/wp-content/uploads/forms/form-registration-update-your-personal-details.pdf
Insulin Pump Consumables Assessment Form –NDSS	https://www.ndss.com.au/wp-content/uploads/forms/insulin-pump-consumables-assessment-form.pdf
Continuous Glucose Monitoring Eligibility Assessment Form – NDSS	https://www.ndss.com.au/living-with-diabetes/managing-diabetes/continuous-glucose-monitoring/
Continuous Glucose Monitoring Update or Termination Form – NDSS	https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/2332e950-1bf4-4ab5-990d-d7f8ba039958.pdf
Diabetes Related Organisations In Australia	
• Australian Diabetes Society • Australian Diabetes Educators Association • Diabetes Australia • National Diabetes Services Scheme • National Association of Diabetes Centres	
Diabetes Australia Position Statements	To view or download all current Diabetes Australia position statements: https://www.diabetesaustralia.com.au/position-statements

Australian Government Departments

- Australian Department of Health
  - BPDC 2016 Minister for Health Presentation – Priorities for the Government in Health can be viewed at https://www.youtube.com/watch?v=w-0QRgDlSS8
- Australian Institute of Health and Welfare
- Federation of Ethnic Communities Council Australia
- Healthdirect Australia
- Food Standards Australia and New Zealand
- Medicare Australia
- National Health and Medical Research Council (NH&MRC)
- Pharmaceutical Benefits Scheme
- Therapeutic Goods Administration

Professional Associations & Organisations

- Australian Diabetes Society (ADS)
- Australian Diabetes Educators Association (ADEA)
- Australian Practice Nurses Association (APNA)
- Australasian Diabetes In Pregnancy Society (ADIPS)
- Australasian Paediatric Endocrine Group (APEG)
- Australasian Podiatry Council
- Cancer Council Australia
- Dietitians Association of Australia
- National Heart Foundation
- Kidney Health Australia
- National Aboriginal Community Controlled Health Organisation
- National Stroke Foundation
- Optometrists Association of Australia
- Palliative Care Australia
- Pharmaceutical Society of Australia
- The Royal Australian College of General Practitioners
- Pharmacy Guild of Australia

International Diabetes Associations

- International Diabetes Federation
- American Diabetes Association
- Diabetes Canada
- Diabetes New Zealand
- Diabetes United Kingdom
- Glycosmedia

Support

- Children with Diabetes (part of the Johnson & Johnson Diabetes Franchise)
- Diabetes Counselling Online
- Diabetes and Emotional Health Handbook and Toolkit

updated 04.02.2020

9. REFERENCES

1. DO IT Study Group. Reports of the EASD Study Groups 1990/1991. Diabetologia. 1991;34 (Suppl 2):I-IX.

2. Krans HMJ, Porta M, Keen H. Monitoring instruments for quality improvement in diabetes care. G Ital Diabetologia. 1993;10:371-7.

3. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. Monitoring the targets of the St Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. The DIABCARE Monitoring Group of the St Vincent Declaration Steering Committee. Diabet Med. 1993;10(4):371-7.

4. Piwernetz K, Bruckmeier A, Johansen KS, Krans HMJ. Diabcare Quality Network in Europe. Diabetes Nutr Metab. 1993;6(6):311-4.

5. Diabetes Australia NSW & NSW Department of Health. Report on the 1993 NSW Diabetes Outcomes Workshop (NDOW). NSW Department of Health; 1993.

6. Rattray A, Colagiuri S, Churches T, Flack JR. NSW diabetes outcomes workshop (NDOW) data collection. Abstract 113, Proceedings of the Australian Diabetes Society Meeting, September 1995, Melbourne.

7. Australian Government Department of Health and Aged Care and Australian Institute of Health and Welfare. National Health Priority Areas Report: Diabetes Mellitus 1998. AIHW Cat. No. PHE 10. Canberra, ACT: Commonwealth Department of Health and Aged Care and AIHW; 1999.

8. Australian Government Department of Health and Aged Care. Australian National Diabetes Strategy 2021-2030. Canberra, ACT: Commonwealth Department of Health and Aged Care; 2021. [Available from: https://www.health.gov.au/sites/default/files/documents/2021/11/australian-national-diabetes-strategy-2021-2030_0.pdf].

9. Australian Institute of Health and Welfare. Meteor metadata online registry. Diabetes (clinical) NBPDS. Canberra, ACT: AIHW; 2005. [Available from: https://meteor.aihw.gov.au/content/304865].

10. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care. 2001;24(10):1815-20.

11. National Board of Health and Welfare. Quality and efficiency of diabetes care in Sweden: National performance assessment 2011. Stockholm, Sweden: NBHW; 2011. [Available from: https://silo.tips/download/quality-and-efficiency-of-diabetes-care-in-sweden-national-performance-assessmen].

12. National Institute for Health and Care Excellence. NICE quality and outcomes framework indicator: diabetes mellitus. London, UK: NICE; [Available from: https://www.nice.org.uk/standards-and-indicators/qofindicators?categories=&page=2].